Consensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis

array:21 ["pii" => "X0873215916514648" "issn" => "08732159" "doi" => "10.1016/j.rppnen.2016.01.003" "estado" => "S300" "fechaPublicacion" => "2016-03-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Rev Port Pneumol. 2016;22:112-22" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 880 "formatos" => array:2 [ "HTML" => 658 "PDF" => 222 ] ] "itemSiguiente" => array:16 [ "pii" => "X0873215916514656" "issn" => "08732159" "doi" => "10.1016/j.rppnen.2015.09.005" "estado" => "S300" "fechaPublicacion" => "2016-03-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Rev Port Pneumol. 2016;22:123-5" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 376 "formatos" => array:2 [ "HTML" => 256 "PDF" => 120 ] ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "Adjuvant chemotherapy in stage IB non-small cell lung carcinoma: A survival analysis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "123" "paginaFinal" => "125" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "D. Coutinho, A. Gonçalves, A. Antunes, S. Campainha, J. Miranda, A. Barroso" "autores" => array:6 [ 0 => array:2 [ "Iniciales" => "D." "apellidos" => "Coutinho" ] 1 => array:2 [ "Iniciales" => "A." "apellidos" => "Gonçalves" ] 2 => array:2 [ "Iniciales" => "A." "apellidos" => "Antunes" ] 3 => array:2 [ "Iniciales" => "S." "apellidos" => "Campainha" ] 4 => array:2 [ "Iniciales" => "J." "apellidos" => "Miranda" ] 5 => array:2 [ "Iniciales" => "A." "apellidos" => "Barroso" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0873215916514656?idApp=UINPBA00004E" "url" => "/08732159/0000002200000002/v0_201604141122/X0873215916514656/v0_201604141122/en/main.assets" ] "itemAnterior" => array:16 [ "pii" => "X087321591651463X" "issn" => "08732159" "doi" => "10.1016/j.rppnen.2015.12.001" "estado" => "S300" "fechaPublicacion" => "2016-03-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Rev Port Pneumol. 2016;22:101-11" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 533 "formatos" => array:2 [ "HTML" => 338 "PDF" => 195 ] ] "en" => array:11 [ "idiomaDefecto" => true "titulo" => "Understanding COPD: A vision on phenotypes, comorbidities and treatment approach" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "101" "paginaFinal" => "111" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "320v22n02-90451463fig1.jpg" "Alto" => 2973 "Ancho" => 2500 "Tamanyo" => 1170702 ] ] "descripcion" => array:1 [ "en" => "Proposed most clinically relevant phenotypes." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "E. Fragoso, S. André, J.P. Boleo-Tomé, V. Areias, J. Munhá, J. Cardoso" "autores" => array:6 [ 0 => array:2 [ "Iniciales" => "E." "apellidos" => "Fragoso" ] 1 => array:2 [ "Iniciales" => "S." "apellidos" => "André" ] 2 => array:2 [ "Iniciales" => "J.P." "apellidos" => "Boleo-Tomé" ] 3 => array:2 [ "Iniciales" => "V." "apellidos" => "Areias" ] 4 => array:2 [ "Iniciales" => "J." "apellidos" => "Munhá" ] 5 => array:2 [ "Iniciales" => "J." "apellidos" => "Cardoso" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X087321591651463X?idApp=UINPBA00004E" "url" => "/08732159/0000002200000002/v0_201604141122/X087321591651463X/v0_201604141122/en/main.assets" ] "asociados" => array:1 [ 0 => array:19 [ "pii" => "S2173511516000440" "issn" => "21735115" "doi" => "10.1016/j.rppnen.2016.03.001" "estado" => "S300" "fechaPublicacion" => "2016-03-01" "aid" => "1149" "copyright" => "Sociedade Portuguesa de Pneumologia" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "edi" "cita" => "Rev Port Pneumol. 2016;22:70-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1670 "formatos" => array:3 [ "EPUB" => 211 "HTML" => 918 "PDF" => 541 ] ] "en" => array:9 [ "idiomaDefecto" => true "cabecera" => "EDITORIAL" "titulo" => "How to handle IPF – the new Portuguese consensus document" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "70" "paginaFinal" => "72" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ulrich Costabel, Francesco Bonella" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Ulrich" "apellidos" => "Costabel" ] 1 => array:2 [ "nombre" => "Francesco" "apellidos" => "Bonella" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173511516000440?idApp=UINPBA00004E" "url" => "/21735115/0000002200000002/v2_201704020101/S2173511516000440/v2_201704020101/en/main.assets" ] ] "en" => array:14 [ "idiomaDefecto" => true "titulo" => "Consensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "112" "paginaFinal" => "122" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "C. Robalo Cordeiro, P. Campos, L. Carvalho, S. Campainha, S. Clemente, L. Figueiredo, J.M. Jesus, A. Marques, C. Souto-Moura, R. Pinto Basto, A. Ribeiro, M. Serrado, A. Morais" "autores" => array:13 [ 0 => array:4 [ "Iniciales" => "C." "apellidos" => "Robalo Cordeiro" "email" => array:1 [ 0 => "carlos.crobalo@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "affa" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor1" ] ] ] 1 => array:3 [ "Iniciales" => "P." "apellidos" => "Campos" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "affb" ] ] ] 2 => array:3 [ "Iniciales" => "L." "apellidos" => "Carvalho" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "affc" ] ] ] 3 => array:3 [ "Iniciales" => "S." "apellidos" => "Campainha" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "d" "identificador" => "affd" ] ] ] 4 => array:3 [ "Iniciales" => "S." "apellidos" => "Clemente" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "e" "identificador" => "affe" ] ] ] 5 => array:3 [ "Iniciales" => "L." "apellidos" => "Figueiredo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "f" "identificador" => "afff" ] ] ] 6 => array:3 [ "Iniciales" => "J.M." "apellidos" => "Jesus" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "g" "identificador" => "affg" ] ] ] 7 => array:3 [ "Iniciales" => "A." "apellidos" => "Marques" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "h" "identificador" => "affh" ] ] ] 8 => array:3 [ "Iniciales" => "C." "apellidos" => "Souto-Moura" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "i" "identificador" => "affi" ] ] ] 9 => array:3 [ "Iniciales" => "R." "apellidos" => "Pinto Basto" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "j" "identificador" => "affj" ] ] ] 10 => array:3 [ "Iniciales" => "A." "apellidos" => "Ribeiro" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "k" "identificador" => "affk" ] ] ] 11 => array:3 [ "Iniciales" => "M." "apellidos" => "Serrado" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "j" "identificador" => "affj" ] ] ] 12 => array:3 [ "Iniciales" => "A." "apellidos" => "Morais" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "h" "identificador" => "affh" ] ] ] ] "afiliaciones" => array:11 [ 0 => array:3 [ "entidad" => "Centre of Pulmonology, Coimbra University Hospital, Coimbra, Portugal" "etiqueta" => "a" "identificador" => "affa" ] 1 => array:3 [ "entidad" => "Imagiology Department, Santa Marta Hospital, Northern Lisbon Hospital Centre, Lisbon, Portugal" "etiqueta" => "b" "identificador" => "affb" ] 2 => array:3 [ "entidad" => "Anatomical Pathology Institute, Faculty of Medicine of the University of Coimbra, Coimbra, Portugal" "etiqueta" => "c" "identificador" => "affc" ] 3 => array:3 [ "entidad" => "Pulmonology Department, Vila Nova de Gaia/Espinho Hospital Centre, Vila Nova de Gaia, Portugal" "etiqueta" => "d" "identificador" => "affd" ] 4 => array:3 [ "entidad" => "Pulmonology Department, Beatriz Ângelo Hospital, Loures, Portugal" "etiqueta" => "e" "identificador" => "affe" ] 5 => array:3 [ "entidad" => "Radiology Department, Santa Marta Hospital, Central Lisbon Hospital Centre, Lisbon, Portugal" "etiqueta" => "f" "identificador" => "afff" ] 6 => array:3 [ "entidad" => "Radiology Department, São João Hospital Centre, Oporto, Portugal" "etiqueta" => "g" "identificador" => "affg" ] 7 => array:3 [ "entidad" => "Pulmonology Department, São João Hospital Centre, Faculty of Medicine of Porto University, Oporto, Portugal" "etiqueta" => "h" "identificador" => "affh" ] 8 => array:3 [ "entidad" => "Pathology Department, São João Hospital Centre, Faculty of Medicine of Porto University, Oporto, Portugal" "etiqueta" => "i" "identificador" => "affi" ] 9 => array:3 [ "entidad" => "Pulmonology II Department, Pulido Valente Hospital, Northern Lisbon Hospital Centre, Lisbon, Portugal" "etiqueta" => "j" "identificador" => "affj" ] 10 => array:3 [ "entidad" => "Anatomical Pathology Department, Pulido Valente Hospital, Northern Lisbon Hospital Centre, Lisbon, Portugal" "etiqueta" => "k" "identificador" => "affk" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "*" "correspondencia" => "Corresponding author. carlos.crobalo@gmail.com" ] ] ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "320v22n02-90451464fig1.jpg" "Alto" => 2688 "Ancho" => 2167 "Tamanyo" => 410222 ] ] "descripcion" => array:1 [ "en" => "IPF diagnosis algorithm. ILD: interstitial lung disease; IPF: idiopathic pulmonary fibrosis; HRCT: high-resolution computed tomography; UIP: usual interstitial pneumonia." ] ] ] "textoCompleto" => "<a name="sec0005" class="elsevierStyleCrossRefs"></a>IntroductionIdiopathic pulmonary fibrosis (IPF) is the most common and fatal of the idiopathic interstitial pneumonias subgroup.<a href="#bib96" class="elsevierStyleCrossRefs">1</a>, <a href="#bib97" class="elsevierStyleCrossRefs">2</a>, <a href="#bib98" class="elsevierStyleCrossRefs">3</a>, <a href="#bib99" class="elsevierStyleCrossRefs">4</a>, <a href="#bib100" class="elsevierStyleCrossRefs">5</a>After the first IPF consensus<a href="#bib101" class="elsevierStyleCrossRefs">6</a> of the American Thoracic Society (ATS)/European Respiratory Society (ERS) in 2000, several studies contributed to a greater knowledge of IPF diagnosis and treatment, which was reflected in the updated international consensus on the diagnosis and management of IPF published in 2011 and signed by the American (ATS), European (ERS), Japanese (JRS) and Latin American Associations (ALAT).<a href="#bib96" class="elsevierStyleCrossRefs">1</a> Since this publication several developments in the IPF management there have been, including diagnostic criteria and therapeutic options.<a href="#bib102" class="elsevierStyleCrossRefs">7</a>, <a href="#bib103" class="elsevierStyleCrossRefs">8</a>, <a href="#bib104" class="elsevierStyleCrossRefs">9</a>, <a href="#bib105" class="elsevierStyleCrossRefs">10</a>, <a href="#bib106" class="elsevierStyleCrossRefs">11</a>Interstitial lung diseases are identified as priority intervention in the Portuguese National Program of Respiratory Diseases<a href="#bib107" class="elsevierStyleCrossRefs">12</a>; nonetheless there is a general consensus about the need for greater awareness for the identification of these patients, enabling an earlier diagnosis and treatment.<a name="sec0010" class="elsevierStyleCrossRefs"></a>DefinitionIPF is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, predominantly in adults over 50 years, limited to the lungs, and associated with the radiologic and/or histopathologic pattern of usual interstitial pneumonia (UIP).<a href="#bib96" class="elsevierStyleCrossRefs">1</a>, <a href="#bib97" class="elsevierStyleCrossRefs">2</a>, <a href="#bib98" class="elsevierStyleCrossRefs">3</a>, <a href="#bib108" class="elsevierStyleCrossRefs">13</a><a name="sec0015" class="elsevierStyleCrossRefs"></a>EpidemiologyDepending on the criteria and methodology adopted in reliable studies,<a href="#bib109" class="elsevierStyleCrossRefs">14</a> IPF incidence ranges between 0.22 and 17.4 per 100,000 person-year, and the prevalence between 14 and 27.9 cases per 100,000 persons. It is unknown if geographic, ethnic, cultural or racial factors influence the incidence and prevalence of IPF.<a href="#bib96" class="elsevierStyleCrossRefs">1</a>, <a href="#bib110" class="elsevierStyleCrossRefs">15</a> IPF is associated with a poor prognosis, with a median survival of 2–3 years after the diagnosis.<a href="#bib111" class="elsevierStyleCrossRefs">16</a>, <a href="#bib112" class="elsevierStyleCrossRefs">17</a>, <a href="#bib113" class="elsevierStyleCrossRefs">18</a><a name="sec0020" class="elsevierStyleCrossRefs"></a>Risk factorsAlthough the aetiology of IPF is unknown, several potential risk factors have been identified including: (a) environmental factors like smoking history of >20 packs/year, exposure to silicon, brass, steel, lead and wood dust, farming and agricultural work, construction of wooden houses<a href="#bib114" class="elsevierStyleCrossRefs">19</a>; (b) genetic factors such as familial pulmonary fibrosis, mutations in the genes that maintain the length of the telomeres (TERT – Telomerase reverse transcriptase, TERC – Telomerase RNA component), mutations in the surfactant protein C gene and mutations in the mucin 5B promoter region (MUC5B)<a href="#bib115" class="elsevierStyleCrossRefs">20</a>, <a href="#bib116" class="elsevierStyleCrossRefs">21</a>, <a href="#bib117" class="elsevierStyleCrossRefs">22</a>, <a href="#bib118" class="elsevierStyleCrossRefs">23</a>; (c) gastro-oesophageal reflux (GER), considered a risk factor for the predisposition and progression of IPF<a href="#bib119" class="elsevierStyleCrossRefs">24</a>, <a href="#bib120" class="elsevierStyleCrossRefs">25</a>; (d) viral infections, although there is no sufficient data to state their role in IPF despite the large number of studies analyzing the etiological risk effect of hepatitis C virus, herpes virus and adenovirus<a href="#bib121" class="elsevierStyleCrossRefs">26</a>, <a href="#bib122" class="elsevierStyleCrossRefs">27</a>; and (e) autoimmunity, that is still being studied but the possible autoimmune origin of IPF is based on the association of radiologic and/or histologic manifestations of UIP to connective tissue diseases.<a href="#bib96" class="elsevierStyleCrossRefs">1</a>, <a href="#bib108" class="elsevierStyleCrossRefs">13</a><a name="sec0025" class="elsevierStyleCrossRefs"></a>DiagnosisThe diagnosis of IPF requires a multidisciplinary approach, including the awareness of general practice physicians, and experienced pulmonologists, radiologists and pathologists in the evaluation and correct treatment of diffuse interstitial lung disease (DILD).<a href="#bib96" class="elsevierStyleCrossRefs">1</a>, <a href="#bib98" class="elsevierStyleCrossRefs">3</a>, <a href="#bib108" class="elsevierStyleCrossRefs">13</a>, <a href="#bib123" class="elsevierStyleCrossRefs">28</a>, <a href="#bib124" class="elsevierStyleCrossRefs">29</a>, <a href="#bib125" class="elsevierStyleCrossRefs">30</a>, <a href="#bib126" class="elsevierStyleCrossRefs">31</a> This approach helps increase diagnostic accuracy and is an internationally accepted recommendation.<a href="#bib123" class="elsevierStyleCrossRefs">28</a>, <a href="#bib124" class="elsevierStyleCrossRefs">29</a><a href="#t0005" class="elsevierStyleCrossRefs">Table 1</a> presents the procedures that should be performed at diagnosis, systematically and occasionally.Table 1. Idiopathic pulmonary fibrosis diagnosis examinations.<a name="t0005" class="elsevierStyleCrossRefs"></a><table><tr align="left"><td>At IPF diagnosis</td></tr><tr align="left"><td>Systematic</td></tr><tr align="left"><td>Chest HRCT</td></tr><tr align="left"><td>Plethysmography and DLCO</td></tr><tr align="left"><td>Arterial blood gas in room air at rest</td></tr><tr align="left"><td>6MWT with measurement of percutaneous oxygen saturation</td></tr><tr align="left"><td>Doppler echocardiography</td></tr><tr align="left"><td> </td></tr><tr align="left"><td>Biology</td></tr><tr align="left"><td>Antinuclear antibodies</td></tr><tr align="left"><td>Anti-citrullinated cyclic peptides antibodies</td></tr><tr align="left"><td>Rheumatoid factor</td></tr><tr align="left"><td>Extractable Nuclear Antigens antibodies</td></tr><tr align="left"><td> </td></tr><tr align="left"><td>Occasional</td></tr><tr align="left"><td>Video-assisted surgical lung biopsy</td></tr><tr align="left"><td>Differential cell count of BAL</td></tr><tr align="left"><td> </td></tr><tr align="left"><td>Depending on context</td></tr><tr align="left"><td>Genetic testing</td></tr><tr align="left"><td>Anti-neutrophil cytoplasmic antibodies</td></tr><tr align="left"><td>Creatine phosphokinase</td></tr><tr align="left"><td>Anti-thyroid antibodies</td></tr><tr align="left"><td>Precipitins (depending on disease presentation)</td></tr><tr align="left"><td>Electrophoresis of serum proteins, immuno-electrophoresis of serum proteins, urine immunofixation and cryoglobulinaemia</td></tr><tr align="left"><td>Exploration for gastro-oesophageal reflux</td></tr><tr align="left"><td>Exploration for sleep apnoea syndrome</td></tr></table>Adapted from Cottin et al. 3 6MWT: 6-min walk test; BAL: bronchoalveolar lavage; DLCO: diffusing capacity of the lung for carbon monoxide; HRCT: high-resolution computed tomography. The general practice physician must be aware of IPF symptoms in order to consider this disease when establishing the initial diagnosis, and to refer IPF suspicious cases to a pulmonologist.The diagnosis of IPF requires the exclusion of other known causes of interstitial lung disease (domestic or occupational environmental exposures, connective tissue disease, drug toxicity) and the presence of a typical histological UIP pattern.<a href="#bib96" class="elsevierStyleCrossRefs">1</a>, <a href="#bib98" class="elsevierStyleCrossRefs">3</a>, <a href="#bib102" class="elsevierStyleCrossRefs">7</a>, <a href="#bib108" class="elsevierStyleCrossRefs">13</a>, <a href="#bib113" class="elsevierStyleCrossRefs">18</a>, <a href="#bib127" class="elsevierStyleCrossRefs">32</a> According to the ATS/ERS recommendations and validated by international societies, in the absence of biopsy, IPF can be diagnosed only based on radiological criteria from the high resolution computed tomography (HRCT).<a href="#bib96" class="elsevierStyleCrossRefs">1</a><a href="#f0005" class="elsevierStyleCrossRefs">Figure 1</a> presents the algorithm proposed for the diagnosis of IPF. In case of IPF suspicion, all the possible associations with UIP radiological pattern must be accurately investigated. Since UIP pattern can be associated with several autoimmune diseases, such as rheumatoid arthritis, systemic sclerosis or Sjögren syndrome or even, although rarely, with ANCA-positive vasculitis, all patients should perform serological autoimmune tests, although positive anti-nuclear antibodies or rheumatoid factor can be detected in up to 20% of IPF cases as an unspecific feature with no association with any particular disorder.<a href="#bib96" class="elsevierStyleCrossRefs">1</a>, <a href="#bib127" class="elsevierStyleCrossRefs">32</a>, <a href="#bib128" class="elsevierStyleCrossRefs">33</a>, <a href="#bib129" class="elsevierStyleCrossRefs">34</a> The presence of serum specific IgG against the antigens that can frequently cause hypersensitivity pneumonitis should also be systematically assessed.<a href="#bib96" class="elsevierStyleCrossRefs">1</a>, <a href="#bib125" class="elsevierStyleCrossRefs">30</a>, <a href="#bib129" class="elsevierStyleCrossRefs">34</a>, <a href="#bib130" class="elsevierStyleCrossRefs">35</a><a name="f0005" class="elsevierStyleCrossRefs"></a><img src="320v22n02-90451464fig1.jpg" alt="IPF diagnosis algorithm. ILD: interstitial lung disease; IPF: idiopathic pulmonary fibrosis; HRCT: high-resolution computed tomography; UIP: usual interstitial pneumonia."></img>Figure 1. IPF diagnosis algorithm. ILD: interstitial lung disease; IPF: idiopathic pulmonary fibrosis; HRCT: high-resolution computed tomography; UIP: usual interstitial pneumonia.Bronchoalveolar lavage (BAL) is not included in this algorithm as a diagnostic procedure since it is not recommended that BAL be systematically performed in all patients, although it may be appropriate for a minority of cases.<a href="#bib98" class="elsevierStyleCrossRefs">3</a>, <a href="#bib131" class="elsevierStyleCrossRefs">36</a>, <a href="#bib132" class="elsevierStyleCrossRefs">37</a>, <a href="#bib133" class="elsevierStyleCrossRefs">38</a>, <a href="#bib134" class="elsevierStyleCrossRefs">39</a> Nevertheless, Centres with experience in this approach might use BAL regularly as it can either rule out or help diagnose IPF, especially when a higher lymphocytosis guides the diagnosis for other entities, as for instance hypersensitivity pneumonitis.<a href="#bib132" class="elsevierStyleCrossRefs">37</a> On the other hand, the use of transbronchial biopsy in the diagnosis of IPF is controversial. Cryobiopsy, although it is not yet widely used and must only be performed in Centres with experience in this procedure, the published data so far shows that cryobiopsy in fibrotic ILDs yields large and well-preserved lung specimens, sufficient to enclose all the UIP characteristic features, with safety and tolerability.<a href="#bib135" class="elsevierStyleCrossRefs">40</a>, <a href="#bib136" class="elsevierStyleCrossRefs">41</a>, <a href="#bib137" class="elsevierStyleCrossRefs">42</a> In a recent cross-sectional study, a comparison of cryobiopsies with surgical lung biopsies in fibrotic ILD by a multidisciplinary committee, conclude a major increase in diagnostic confidence after the addition of cryobiopsies similar to surgical lung biopsy (SLB) in IPF diagnosis (from 29% to 63%, p = 0.0003 and from 30% to 65%, p = 0.0016 of high confidence in the bronchoscopic lung cryobiopsy group and SLB group respectively), which constitutes robust evidence of the potential role of this bronchologic procedure.<a href="#bib138" class="elsevierStyleCrossRefs">43</a><a name="sec0030" class="elsevierStyleCrossRefs"></a>High resolution computed tomographyThe purpose of HRCT is to identify the typical pattern of changes of UIP (<a href="#t0010" class="elsevierStyleCrossRefs">Table 2</a>) or other patterns that may be present, supporting the diagnosis of other lung diseases. To standardize these radiological criteria, the report should use descriptive concepts based on the terminology recommended by Fleischner Society.<a href="#bib139" class="elsevierStyleCrossRefs">44</a>Table 2. High-resolution computed tomography's idiopathic pulmonary fibrosis/usual interstitial pneumonia diagnosis criteria.<a name="t0010" class="elsevierStyleCrossRefs"></a><table><tr align="left"><td>UIP pattern (all of the following)</td><td>Possible UIP pattern (all of the following)</td><td>UIP-IPF pattern (1 + 2)</td></tr><tr align="left"><td>1-Subpleural, basal (predominant distribution)</td><td>1-Subpleural, basal (predominant distribution)</td><td>1-All of UIP pattern</td></tr><tr align="left"><td>2-Reticulation</td><td>2-Reticulation</td><td>2-Absence of findings that do not support a UIP pattern</td></tr><tr align="left"><td>3-Honeycombing with or without traction bronchiectasis</td><td>3-Absence of findings that do not support a UIP pattern</td><td> </td></tr></table>Adapted from Raghu et al. 1 IPF: idiopathic pulmonary fibrosis; UIP: usual interstitial pneumonia. The identification of lung honeycombing is crucial for the diagnosis of IPF – they are cystic axial, confluent or layered images, with diameters of 3–10 mm, reaching 2.5 cm. The distribution is usually subpleural or in the reticulation areas.<a href="#bib140" class="elsevierStyleCrossRefs">45</a>, <a href="#bib141" class="elsevierStyleCrossRefs">46</a>, <a href="#bib142" class="elsevierStyleCrossRefs">47</a>, <a href="#bib143" class="elsevierStyleCrossRefs">48</a>, <a href="#bib144" class="elsevierStyleCrossRefs">49</a>There are two aspects that may raise doubts in the HRTC interpretation: the distinction between honeycombing and traction bronchiolectasis and fibrosis with emphysema. The differential diagnosis is a challenge even for an experienced radiologist.<a href="#bib142" class="elsevierStyleCrossRefs">47</a>, <a href="#bib144" class="elsevierStyleCrossRefs">49</a>, <a href="#bib145" class="elsevierStyleCrossRefs">50</a> The 2011 ATS/ERS/JRS/ALAT multidisciplinary consensus<a href="#bib96" class="elsevierStyleCrossRefs">1</a> stated that the identification of four typical findings establishes the definite diagnosis of UIP: 1 – subpleural and basal lung lesions predominance; 2 – reticulation; 3 – honeycombing with/without traction bronchiectasis/bronchiolectasis; 4 – absence of findings that do not support a UIP pattern (<a href="#t0010" class="elsevierStyleCrossRefs">Table 2</a>, <a href="#t0015" class="elsevierStyleCrossRefs">Table 3</a>; <a href="#f0010" class="elsevierStyleCrossRefs">Figure 2</a>).Table 3. Inconsistent criteria in the high-resolution computed tomography's idiopathic pulmonary fibrosis/usual interstitial pneumonia diagnosis.<a name="t0015" class="elsevierStyleCrossRefs"></a><table><tr align="left"><td>Any of the following</td></tr><tr align="left"><td>Predominance of middle or upper distribution</td></tr><tr align="left"><td>Peri-bronchovascular distribution</td></tr><tr align="left"><td>Reticular ground glass opacities</td></tr><tr align="left"><td>Micronodules (bilateral and upper lobes predominance)</td></tr><tr align="left"><td>Axial cysts (multiple, bilateral, distant from the areas of honeycombing)</td></tr><tr align="left"><td>Mosaic pattern, diffuse/air trapping (bilateral, in three or more lobes)</td></tr><tr align="left"><td>Segment/lobar consolidation</td></tr></table>Adapted from Raghu et al. 1 <a name="f0010" class="elsevierStyleCrossRefs"></a><img src="320v22n02-90451464fig2a.jpg" alt="UIP/IPF identification in HRCT and histopathology. Case 1 – a: Common histopathological features of UIP/IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant. HE 100×. Case 1 – b: The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces. HE 100×. Case 1 – c: The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells, either fibroblasts or miofibroblasts, with collagen deposition. Elastin-van Gieson 100×. Case 2 – a: Irregular confluent air spaces with typical subpleural localization of UIP/IPF honeycombing with interstitium enlargement by fusiform cells. HE 100×. Case 2 – b: The adjacent lobular parenchyma accentuate histopathological heterogeneity, starting by overinflation and pseudo emphysema morphology. HE 100×. Case 2 – c: The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization. HE 100×. Case 3 – a: Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix; lymphocytes are seen. PAS 200×. Case 3 – b: UIP/IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule. HE 100×."></img>Figure 2. UIP/IPF identification in HRCT and histopathology. Case 1 – a: Common histopathological features of UIP/IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant. HE 100×. Case 1 – b: The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces. HE 100×. Case 1 – c: The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells, either fibroblasts or miofibroblasts, with collagen deposition. Elastin-van Gieson 100×. Case 2 – a: Irregular confluent air spaces with typical subpleural localization of UIP/IPF honeycombing with interstitium enlargement by fusiform cells. HE 100×. Case 2 – b: The adjacent lobular parenchyma accentuate histopathological heterogeneity, starting by overinflation and pseudo emphysema morphology. HE 100×. Case 2 – c: The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization. HE 100×. Case 3 – a: Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix; lymphocytes are seen. PAS 200×. Case 3 – b: UIP/IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule. HE 100×.<a name="f0010" class="elsevierStyleCrossRefs"></a><img src="320v22n02-90451464fig2b.jpg" alt="UIP/IPF identification in HRCT and histopathology. Case 1 – a: Common histopathological features of UIP/IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant. HE 100×. Case 1 – b: The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces. HE 100×. Case 1 – c: The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells, either fibroblasts or miofibroblasts, with collagen deposition. Elastin-van Gieson 100×. Case 2 – a: Irregular confluent air spaces with typical subpleural localization of UIP/IPF honeycombing with interstitium enlargement by fusiform cells. HE 100×. Case 2 – b: The adjacent lobular parenchyma accentuate histopathological heterogeneity, starting by overinflation and pseudo emphysema morphology. HE 100×. Case 2 – c: The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization. HE 100×. Case 3 – a: Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix; lymphocytes are seen. PAS 200×. Case 3 – b: UIP/IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule. HE 100×."></img>Figure 2. UIP/IPF identification in HRCT and histopathology. Case 1 – a: Common histopathological features of UIP/IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant. HE 100×. Case 1 – b: The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces. HE 100×. Case 1 – c: The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells, either fibroblasts or miofibroblasts, with collagen deposition. Elastin-van Gieson 100×. Case 2 – a: Irregular confluent air spaces with typical subpleural localization of UIP/IPF honeycombing with interstitium enlargement by fusiform cells. HE 100×. Case 2 – b: The adjacent lobular parenchyma accentuate histopathological heterogeneity, starting by overinflation and pseudo emphysema morphology. HE 100×. Case 2 – c: The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization. HE 100×. Case 3 – a: Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix; lymphocytes are seen. PAS 200×. Case 3 – b: UIP/IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule. HE 100×.<a name="f0010" class="elsevierStyleCrossRefs"></a><img src="320v22n02-90451464fig2c.jpg" alt="UIP/IPF identification in HRCT and histopathology. Case 1 – a: Common histopathological features of UIP/IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant. HE 100×. Case 1 – b: The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces. HE 100×. Case 1 – c: The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells, either fibroblasts or miofibroblasts, with collagen deposition. Elastin-van Gieson 100×. Case 2 – a: Irregular confluent air spaces with typical subpleural localization of UIP/IPF honeycombing with interstitium enlargement by fusiform cells. HE 100×. Case 2 – b: The adjacent lobular parenchyma accentuate histopathological heterogeneity, starting by overinflation and pseudo emphysema morphology. HE 100×. Case 2 – c: The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization. HE 100×. Case 3 – a: Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix; lymphocytes are seen. PAS 200×. Case 3 – b: UIP/IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule. HE 100×."></img>Figure 2. UIP/IPF identification in HRCT and histopathology. Case 1 – a: Common histopathological features of UIP/IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant. HE 100×. Case 1 – b: The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces. HE 100×. Case 1 – c: The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells, either fibroblasts or miofibroblasts, with collagen deposition. Elastin-van Gieson 100×. Case 2 – a: Irregular confluent air spaces with typical subpleural localization of UIP/IPF honeycombing with interstitium enlargement by fusiform cells. HE 100×. Case 2 – b: The adjacent lobular parenchyma accentuate histopathological heterogeneity, starting by overinflation and pseudo emphysema morphology. HE 100×. Case 2 – c: The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization. HE 100×. Case 3 – a: Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix; lymphocytes are seen. PAS 200×. Case 3 – b: UIP/IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule. HE 100×.The HRCT positive predictive value in the diagnosis of UIP is 90–100%. The histopathology may also establish a UIP diagnosis in patients with no UIP lesions in the HRTC.The 2011 official ATS/ERS/JRS/ALAT consensus established the use of “definitive” and “possible” IPF; these definitions simplify the definitive diagnosis except for the other patients. According with to this multidisciplinary consensus, the diagnosis of UIP/IPF must be based on the consensus between the clinician, the radiologist and the pathologist.<a href="#bib96" class="elsevierStyleCrossRefs">1</a><a name="sec0035" class="elsevierStyleCrossRefs"></a>HistopathologyA surgical lung biopsy should establish the diagnosis of IPF if there are doubts about the presence of a definitive UIP typical pattern in the HRCT interpretation. In patients with suspected IPF, surgical lung biopsies should be obtained from multiple lobes, avoiding the extremity of the lingula and middle lobe.<a href="#bib96" class="elsevierStyleCrossRefs">1</a>, <a href="#bib146" class="elsevierStyleCrossRefs">51</a>The histological pattern of UIP must present: 1 – marked fibrosis/architectural distortion, with or without honeycombing in a predominantly subpleural/paraseptal distribution; 2 – patchy involvement of lung parenchyma by fibrosis; 3 – fibroblast foci; 4 – absence of features against a diagnosis of UIP suggesting an alternate diagnosis<a href="#bib96" class="elsevierStyleCrossRefs">1</a>, <a href="#bib146" class="elsevierStyleCrossRefs">51</a> (<a href="#f0010" class="elsevierStyleCrossRefs">Figure 2</a>).In some diseases, like rheumatoid arthritis, chronic hypersensitivity pneumonitis or drug-induced pneumonitis, asbestosis and familial fibrosis, a histological pattern indistinguishable from UIP can be observed, so the presence of granulomas, asbestos bodies, specific infections or other exogenous agents must be discarded in the biopsy.<a href="#bib108" class="elsevierStyleCrossRefs">13</a>, <a href="#bib146" class="elsevierStyleCrossRefs">51</a>The biopsy should only be performed after a multidisciplinary meeting where IPF diagnosis was not defined by HRCT; if the biopsy is performed, its results should again be discussed in a multidisciplinary meeting.<a href="#bib146" class="elsevierStyleCrossRefs">51</a><a name="sec0040" class="elsevierStyleCrossRefs"></a>Follow-upIt is recommended that IPF patients perform a follow-up clinic visit every 3–6 months. <a href="#t0020" class="elsevierStyleCrossRefs">Table 4</a> presents the main examinations that are useful for IPF management.Table 4. Idiopathic pulmonary fibrosis management examinations.<a name="t0020" class="elsevierStyleCrossRefs"></a><table><tr align="left"><td>During IPF follow-up</td></tr><tr align="left"><td>Every 6 months</td></tr><tr align="left"><td>FVC and DLCO</td></tr><tr align="left"><td>Arterial blood gas in room air</td></tr><tr align="left"><td>6MWT</td></tr><tr align="left"><td>Chest X ray</td></tr><tr align="left"><td> </td></tr><tr align="left"><td>Depending on context</td></tr><tr align="left"><td>Chest HRCT</td></tr><tr align="left"><td>Doppler echocardiography</td></tr><tr align="left"><td>TLC</td></tr><tr align="left"><td>Right heart catheterization</td></tr></table>Adapted from Cottin et al. 3 6MWT: 6-min walk test; DLCO: diffusing capacity of the lung for carbon monoxide; FVC: forced vital capacity; HRCT: high-resolution computed tomography; TLC: total lung capacity. <a name="sec0045" class="elsevierStyleCrossRefs"></a>Patient flowSetting an IPF patient flow, which defines the several steps from diagnosis to treatment, may represent the identification of more cases of IPF, in a shorter period of time and in early stages of the disease (<a href="#f0015" class="elsevierStyleCrossRefs">Figure 3</a>).<a name="f0015" class="elsevierStyleCrossRefs"></a><img src="320v22n02-90451464fig3.jpg" alt="Idiopathic pulmonary fibrosis patient flow. HRCT: high-resolution computed tomography."></img>Figure 3. Idiopathic pulmonary fibrosis patient flow. HRCT: high-resolution computed tomography.<a name="sec0050" class="elsevierStyleCrossRefs"></a>Pharmacological treatmentThe therapeutic strategy in IPF should be individualized for each patient, considering the evaluation of potential benefits and risks. It is more important to take into account the clinical behaviour than the respiratory function parameters.<a href="#bib147" class="elsevierStyleCrossRefs">52</a>Nintedanib and pirfenidone, two compounds with pleiotropic mechanisms of action are, to date, the two drugs with confirmed efficacy in slowing functional decline and disease progression in IPF patients.<a href="#bib102" class="elsevierStyleCrossRefs">7</a>, <a href="#bib148" class="elsevierStyleCrossRefs">53</a>, <a href="#bib149" class="elsevierStyleCrossRefs">54</a><a name="sec0055" class="elsevierStyleCrossRefs"></a>NintedanibNintedanib is a tyrosine kinase inhibitor small molecule that targets receptors of growth factors, specifically inhibits platelet-derived growth factor receptor (PDGFR), fibroblasts growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR),<a href="#bib150" class="elsevierStyleCrossRefs">55</a>, <a href="#bib151" class="elsevierStyleCrossRefs">56</a>, <a href="#bib152" class="elsevierStyleCrossRefs">57</a> involved in the lung fibrosis mechanism. It is believed that nintedanib reduces the progression of the disease and the decline in lung function by blocking the signalling pathways involved in the fibrotic processes.<a href="#bib150" class="elsevierStyleCrossRefs">55</a>, <a href="#bib151" class="elsevierStyleCrossRefs">56</a>, <a href="#bib152" class="elsevierStyleCrossRefs">57</a>The TOMORROW Phase II trial showed that nintedanib, 150 mg twice daily, was effective in reducing forced vital capacity (FVC) decline, in preventing acute exacerbations, and preserving health-related quality of life (HRQoL).<a href="#bib104" class="elsevierStyleCrossRefs">9</a> The phase III INPULSIS-1 and INPULSIS-2 trials, showed that nintedanib slowed disease progression, reducing the annual rate of lung function decline of 50%.<a href="#bib106" class="elsevierStyleCrossRefs">11</a> It also presented a 68% reduction of adjudicated acute exacerbations,<a href="#bib106" class="elsevierStyleCrossRefs">11</a> which can be crucial since approximately 50% of IPF acute exacerbation admitted patients die during hospitalization.<a href="#bib153" class="elsevierStyleCrossRefs">58</a> After the first publication further subgroup analysis of pooled data from the INPULSIS trials demonstrated that nintedanib slowed disease progression by reducing the annual rate of FVC decline independently of the FVC value (FVC >80% versus <80% or FVC >70% versus <70%), of the presence of emphysema at baseline, of the presence of honeycombing and/or biopsy confirmation of UIP or in the absence of both, namely the presence of “possible UIP” on HRCT scan without histology confirmation.Although these studies were not dimensioned to detect statistical differences in mortality, the pooled analysis of data from the TOMORROW and INPULSIS trials shows a trend towards reduction in mortality, since after 52 weeks the proportion of patients who died from any cause was 5.8% in the nintendanib arm and 8.3% in the placebo group (HR 0.70 [95% CI: 0.46, 1.08]; p = 0.0955). Respiratory mortality was also comparatively low in the nintendanib arm (3.6% versus 5.7% – HR 0.62 [95% CI: 0.37, 1.06]; p = 0.0779).<a href="#bib106" class="elsevierStyleCrossRefs">11</a>, <a href="#bib154" class="elsevierStyleCrossRefs">59</a>The most frequent adverse events during these trials were diarrhoea, nausea and vomiting, that can be easily managed in most patients.<a href="#bib106" class="elsevierStyleCrossRefs">11</a>Nintedanib is approved in the US and EU for the treatment of IPF patients, regardless of disease severity, under the brand name OFEV®.<a name="sec0060" class="elsevierStyleCrossRefs"></a>PirfenidonePirfenidone is a pyridine compound with antifibrotic and anti-inflammatory properties, indicated for the treatment of mild to moderate IPF.<a href="#bib155" class="elsevierStyleCrossRefs">60</a> The mechanism of action of pirfenidone has not been fully established, but it is known that pirfenidone attenuates fibroblast proliferation, production of fibrosis-associated proteins and cytokines, and the increased biosynthesis and accumulation of extracellular matrix in response to cytokine growth factors such as transforming growth factor-beta (TGF-β) and platelet-derived growth factor (PDGF).<a href="#bib155" class="elsevierStyleCrossRefs">60</a>Despite the conflicting outcomes related to FVC decline in the CAPACITY trials 004 and 006, the pooled data <a href="#bib103" class="elsevierStyleCrossRefs">8</a> showed a pirfenidone treatment effect in percentage predicted FVC at week 72 with a dose of 2403 mg/day (−8.5% versus −11.0%; p = 0.005) and a smaller proportion of patients with a FVC decline ≥10%. Pirfenidone also prolonged progression free survival by 23% when compared with placebo.<a href="#bib103" class="elsevierStyleCrossRefs">8</a> A 31% relative difference favouring pirfenidone<a href="#bib103" class="elsevierStyleCrossRefs">8</a> was noted related to 6-min walk test (6MWT) also at week 72. The posterior phase III ASCEND trial showed a reduction of 47.9% of patients with a FVC percentage predicted value decline ≥10% or who died.<a href="#bib105" class="elsevierStyleCrossRefs">10</a> There was also an increase of 132.5% in proportion of patients with no decline in FVC (p < 0.001).<a href="#bib105" class="elsevierStyleCrossRefs">10</a> A reduced decline in 6MWT (p = 0.04) and an improved progression free survival (p < 0.001) were also noted.<a href="#bib105" class="elsevierStyleCrossRefs">10</a>Moreover, in a pooled analysis enclosing CAPACITY and ASCEND trials, there was a significant difference in death cases from any causes between patients treated with pirfenidone and placebo (p = 0.01) and death related with IPF (p = 0.006).<a href="#bib105" class="elsevierStyleCrossRefs">10</a>In a recent pooled data analysis of outcomes at 1 year in CAPACITY and ASCEND trials including a total of 1247 patients pirfenidone reduced the proportion of patients with a ≥10% decline in FVC percentage or death by 43.8% (95% CI 29.3–55.4%) and increased the proportion of patients with no decline by 59.3% (95% CI 29.0–96.8%). Progression free survival, 6MWT and dyspnoea also showed a positive impact from pirfenidone. These results provided further evidence about the benefit of pirfenidone in IPF disease progression.<a href="#bib156" class="elsevierStyleCrossRefs">61</a>The most common adverse events during these trials were photosensibility, gastro-intestinal occurrences and gastro-oesophageal reflux, generally reversible with dose reductions.<a href="#bib103" class="elsevierStyleCrossRefs">8</a>, <a href="#bib105" class="elsevierStyleCrossRefs">10</a>, <a href="#bib157" class="elsevierStyleCrossRefs">62</a>, <a href="#bib158" class="elsevierStyleCrossRefs">63</a>, <a href="#bib159" class="elsevierStyleCrossRefs">64</a>Pirfenidone is approved for the treatment of mild to moderate IPF patients, under the brand name of Esbriet®.Although some data is available related with the concomitant therapy with nintedanib and pirfenidone, this approach cannot be recommended since its efficacy and tolerability is not sufficiently evidenced.<a href="#bib160" class="elsevierStyleCrossRefs">65</a><a name="sec0065" class="elsevierStyleCrossRefs"></a>Other drugsAfter the IFIGENIA study,<a href="#bib161" class="elsevierStyleCrossRefs">66</a> N-acetylcysteine (NAC) combined with prednisone and azathioprine was the treatment of choice for several years.<a href="#bib96" class="elsevierStyleCrossRefs">1</a> With the presentation of the subsequent PANTHER study,<a href="#bib162" class="elsevierStyleCrossRefs">67</a> which showed higher mortality and hospital admissions in patients receiving NAC combination therapy compared to placebo or NAC alone, the triple therapy is not recommended.<a href="#bib96" class="elsevierStyleCrossRefs">1</a> Additionally, NAC as monotherapy did not show efficacy versus placebo.<a href="#bib163" class="elsevierStyleCrossRefs">68</a>Various compounds, including anti-coagulants, interferon gamma-1b, anti-acids, anti-inflammatory and vasodilator agents<a href="#bib120" class="elsevierStyleCrossRefs">25</a>, <a href="#bib135" class="elsevierStyleCrossRefs">40</a>, <a href="#bib164" class="elsevierStyleCrossRefs">69</a>, <a href="#bib165" class="elsevierStyleCrossRefs">70</a>, <a href="#bib166" class="elsevierStyleCrossRefs">71</a>, <a href="#bib167" class="elsevierStyleCrossRefs">72</a>, <a href="#bib168" class="elsevierStyleCrossRefs">73</a>, <a href="#bib169" class="elsevierStyleCrossRefs">74</a>, <a href="#bib170" class="elsevierStyleCrossRefs">75</a>, <a href="#bib171" class="elsevierStyleCrossRefs">76</a>, <a href="#bib172" class="elsevierStyleCrossRefs">77</a>, <a href="#bib173" class="elsevierStyleCrossRefs">78</a>, <a href="#bib174" class="elsevierStyleCrossRefs">79</a>, <a href="#bib175" class="elsevierStyleCrossRefs">80</a>, <a href="#bib176" class="elsevierStyleCrossRefs">81</a> have been tested in IPF patients but have not demonstrated definitive efficacy for the treatment of IPF. In addition, there are currently several ongoing clinical trials results of which will be available in the near future.<a name="sec0070" class="elsevierStyleCrossRefs"></a>Non-pharmacological treatment<a name="sec0075" class="elsevierStyleCrossRefs"></a>Respiratory rehabilitationPulmonary rehabilitation in IPF has showed an improvement in walking distance, symptoms and HRQoL. Although the long term benefit of rehabilitation is not demonstrated, it is recommended for the majority of patients, namely in early stages of the disease.<a href="#bib96" class="elsevierStyleCrossRefs">1</a>, <a href="#bib177" class="elsevierStyleCrossRefs">82</a>, <a href="#bib178" class="elsevierStyleCrossRefs">83</a><a name="sec0080" class="elsevierStyleCrossRefs"></a>Oxygen therapyAlthough there are no specific data concerning the use of long-term oxygen therapy in patients with IPF, based on chronic obstructive pulmonary disease (COPD) and chronic respiratory failures studies, it is recommended to all IPF patients with resting hypoxaemia.<a href="#bib96" class="elsevierStyleCrossRefs">1</a><a name="sec0085" class="elsevierStyleCrossRefs"></a>Lung transplantIn cases that meet the criteria, lung transplant must be always kept in mind since it is, according to the international recommendations, the most effective and reliable treatment for patients with IPF. Lung transplantation 5-years survival rate ranges from 50% to 56% and 10-years survival rate is 30%.<a href="#bib96" class="elsevierStyleCrossRefs">1</a>, <a href="#bib179" class="elsevierStyleCrossRefs">84</a>, <a href="#bib180" class="elsevierStyleCrossRefs">85</a><a name="sec0090" class="elsevierStyleCrossRefs"></a>Treatment of complications and comorbidities<a name="sec0095" class="elsevierStyleCrossRefs"></a>Acute exacerbationHigh-dose corticosteroid therapy with or without immunosuppressive agents, namely cyclophosphamide, and wide spectrum antibiotics, are the most widely used treatments for the acute exacerbation of IPF despite the lack of conclusive evidence demonstrating their benefits.<a href="#bib96" class="elsevierStyleCrossRefs">1</a>, <a href="#bib181" class="elsevierStyleCrossRefs">86</a>, <a href="#bib182" class="elsevierStyleCrossRefs">87</a><a name="sec0100" class="elsevierStyleCrossRefs"></a>Gastro-oesophageal refluxAsymptomatic GER is common in IPF and may impact IPF natural history and progression.<a href="#bib183" class="elsevierStyleCrossRefs">88</a> An analysis of data from three randomized controlled trials showed that IPF patients taking proton pump inhibitors (PPI) and/or H2 inhibitors significantly slower decline in FVC over time.<a href="#bib120" class="elsevierStyleCrossRefs">25</a> According to the international recommendations, asymptomatic GER should be treated in the majority of patients with IPF, namely with PPI.<a href="#bib96" class="elsevierStyleCrossRefs">1</a>, <a href="#bib148" class="elsevierStyleCrossRefs">53</a><a name="sec0105" class="elsevierStyleCrossRefs"></a>Pulmonary hypertensionIn two uncontrolled prospective studies of sildenafil in patients with pulmonary hypertension in context of IPF, walk distance and pulmonary haemodynamics improved after 8–12 weeks of treatment.<a href="#bib184" class="elsevierStyleCrossRefs">89</a>, <a href="#bib185" class="elsevierStyleCrossRefs">90</a> In the randomized controlled STEP-IPF (Sildenafil Trial of Exercise Performance in IPF) trial, comparing 20 mg tid of sildenafil and placebo over 12 weeks, no significant improvement of the 6MWT (primary end-point) was observed; however arterial oxygenation, diffusing capacity of the lung for carbon monoxide (DLCO), dyspnoea and quality of life were improved in patients on sildenafil.<a href="#bib175" class="elsevierStyleCrossRefs">80</a>However, in a subgroup analysis of patients with right ventricular systolic dysfunction echocardiogram-documented, sildenafil treatment resulted in a significant improvement in the primary outcome of 6MWT (mean distance, 99.3 m; 95% CI 22.3–176.2 m).<a href="#bib186" class="elsevierStyleCrossRefs">91</a> Considering these results, although without a clear recommendation, sildenafil can be one option in patients with IPF and pulmonary hypertension with right ventricular dysfunction.Due to lack of evidence, any drug from prostacycline analogues or endothelin receptor antagonists (ERA) are not indicated for use in IPF.<a href="#bib147" class="elsevierStyleCrossRefs">52</a> Moreover, ambrisentan, an ERA, is contraindicated in IPF, since the ARTEMIS-IPF randomized controlled trial showed an increase number of hospitalizations for respiratory complications.<a href="#bib187" class="elsevierStyleCrossRefs">92</a><a name="sec0110" class="elsevierStyleCrossRefs"></a>Palliative careThe aim of palliative care is to improve patients’ quality of life. It is important to take into account not only the symptoms related with the disease progression, like cough and dyspnoea, where codeine and morphine have shown to be effective, but also psychological aspects inherent to those who face this poor prognostic and great disabling disease.<a href="#bib96" class="elsevierStyleCrossRefs">1</a>, <a href="#bib188" class="elsevierStyleCrossRefs">93</a>, <a href="#bib189" class="elsevierStyleCrossRefs">94</a>, <a href="#bib190" class="elsevierStyleCrossRefs">95</a><a name="sec0115" class="elsevierStyleCrossRefs"></a>ConclusionsTo change the scenario of this devastating disease, early identification and referral of IPF patients to a specialized centre is needed. Training of General Practitioners and further awareness of pulmonologists not specialized in IPF is essential to achieve this.Every patient older than 50 years of age, with exertional dyspnoea and dry, non-productive cough, with ongoing or previous smoking habits and bi-basal crackles on auscultation, should have rapid access to a multidisciplinary team.This multidisciplinary approach demands the judicious use, not only of HRCT information and histopathology when needed, but also of all non-standardized data available in individual patients, such as BAL, serology tests and biomarkers.Unfortunately specific biomarkers are yet to be found and less invasive methods to reach lung tissue are far from being established.Nevertheless recent advances in clinical research allowed the release of new and promising molecules, nintedanib and pirfenidone, two antifibrotic drugs with diverse mechanisms of action that presented efficacy in slowing functional decline and disease progression in IPF patients.Finally it must be stressed that in IPF the therapeutic strategy should be individualized to each patient, considering, not only the evaluation of potential benefits and risks, but also and most importantly, taking into account the clinical behaviour of the disease.Corresponding author. carlos.crobalo@gmail.com" "pdfFichero" => "320v22n02a90451464pdf001.pdf" "tienePdf" => true "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec640949" "palabras" => array:4 [ 0 => "Idiopathic pulmonary fibrosis" 1 => "Guideline" 2 => "Diagnosis" 3 => "Therapeutics" ] ] ] ] "tieneResumen" => true "resumen" => array:1 [ "en" => array:1 [ "resumen" => "Idiopathic pulmonary fibrosis is a rare interstitial lung disease included in the Idiopathic Interstitial Pneumonias group. Although several potential risk factors have been described, it is a progressive fibrosing disease of unknown cause affecting mainly adults over 50 years and associated with a poor prognosis, reflected in a median survival of 2–3 years after diagnosis.The concept of a multidisciplinary working group for the diagnosis of idiopathic pulmonary fibrosis is based on the need to have experienced pulmonologists, radiologists and pathologists in the evaluation and correct treatment of the disease, and requires the use of all available data about individual patients, standardized (largely through High Resolution Computed Tomography and pathology when needed) as well as non-standardized data (laboratory, serology and biomarkers). This approach helps to increase diagnostic accuracy and is an internationally accepted recommendation.In regard to therapy, the situation has changed radically since the publication of the ATS/ERS/JRS/ALAT 2011 guidelines on the diagnosis and management of idiopathic pulmonary fibrosis where it was stressed that no proven therapy exists for this disease.Currently besides non-pharmacological treatment, therapy of complications and comorbidities and palliative care, nintedanib and pirfenidone, two compounds with pleiotropic mechanisms of action, are to date, the two drugs with confirmed efficacy in slowing functional decline and disease progression in idiopathic pulmonary fibrosis patients." ] ] "multimedia" => array:10 [ 0 => array:8 [ "identificador" => "fig1" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "320v22n02-90451464fig1.jpg" "Alto" => 2688 "Ancho" => 2167 "Tamanyo" => 410222 ] ] "descripcion" => array:1 [ "en" => "IPF diagnosis algorithm. ILD: interstitial lung disease; IPF: idiopathic pulmonary fibrosis; HRCT: high-resolution computed tomography; UIP: usual interstitial pneumonia." ] ] 1 => array:8 [ "identificador" => "fig2" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "320v22n02-90451464fig2a.jpg" "Alto" => 1360 "Ancho" => 1800 "Tamanyo" => 1230542 ] ] "descripcion" => array:1 [ "en" => "UIP/IPF identification in HRCT and histopathology. Case 1 ¿ a: Common histopathological features of UIP/IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant. HE 100×. Case 1 ¿ b: The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces. HE 100×. Case 1 ¿ c: The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells, either fibroblasts or miofibroblasts, with collagen deposition. Elastin-van Gieson 100×. Case 2 ¿ a: Irregular confluent air spaces with typical subpleural localization of UIP/IPF honeycombing with interstitium enlargement by fusiform cells. HE 100×. Case 2 ¿ b: The adjacent lobular parenchyma accentuate histopathological heterogeneity, starting by overinflation and pseudo emphysema morphology. HE 100×. Case 2 ¿ c: The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization. HE 100×. Case 3 ¿ a: Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix; lymphocytes are seen. PAS 200×. Case 3 ¿ b: UIP/IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule. HE 100×." ] ] 2 => array:8 [ "identificador" => "fig3" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "320v22n02-90451464fig2b.jpg" "Alto" => 1361 "Ancho" => 1800 "Tamanyo" => 1118548 ] ] "descripcion" => array:1 [ "en" => "UIP/IPF identification in HRCT and histopathology. Case 1 ¿ a: Common histopathological features of UIP/IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant. HE 100×. Case 1 ¿ b: The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces. HE 100×. Case 1 ¿ c: The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells, either fibroblasts or miofibroblasts, with collagen deposition. Elastin-van Gieson 100×. Case 2 ¿ a: Irregular confluent air spaces with typical subpleural localization of UIP/IPF honeycombing with interstitium enlargement by fusiform cells. HE 100×. Case 2 ¿ b: The adjacent lobular parenchyma accentuate histopathological heterogeneity, starting by overinflation and pseudo emphysema morphology. HE 100×. Case 2 ¿ c: The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization. HE 100×. Case 3 ¿ a: Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix; lymphocytes are seen. PAS 200×. Case 3 ¿ b: UIP/IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule. HE 100×." ] ] 3 => array:8 [ "identificador" => "fig4" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "320v22n02-90451464fig2c.jpg" "Alto" => 664 "Ancho" => 1800 "Tamanyo" => 650314 ] ] "descripcion" => array:1 [ "en" => "UIP/IPF identification in HRCT and histopathology. Case 1 ¿ a: Common histopathological features of UIP/IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant. HE 100×. Case 1 ¿ b: The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces. HE 100×. Case 1 ¿ c: The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells, either fibroblasts or miofibroblasts, with collagen deposition. Elastin-van Gieson 100×. Case 2 ¿ a: Irregular confluent air spaces with typical subpleural localization of UIP/IPF honeycombing with interstitium enlargement by fusiform cells. HE 100×. Case 2 ¿ b: The adjacent lobular parenchyma accentuate histopathological heterogeneity, starting by overinflation and pseudo emphysema morphology. HE 100×. Case 2 ¿ c: The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization. HE 100×. Case 3 ¿ a: Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix; lymphocytes are seen. PAS 200×. Case 3 ¿ b: UIP/IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule. HE 100×." ] ] 4 => array:8 [ "identificador" => "fig5" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "320v22n02-90451464fig3.jpg" "Alto" => 3103 "Ancho" => 1000 "Tamanyo" => 398528 ] ] "descripcion" => array:1 [ "en" => "Idiopathic pulmonary fibrosis patient flow. HRCT: high-resolution computed tomography." ] ] 5 => array:6 [ "identificador" => "fig6" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "descripcion" => array:1 [ "en" => "IPF diagnosis algorithm. ILD: interstitial lung disease; IPF: idiopathic pulmonary fibrosis; HRCT: high-resolution computed tomography; UIP: usual interstitial pneumonia." ] ] 6 => array:6 [ "identificador" => "fig7" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "descripcion" => array:1 [ "en" => "UIP/IPF identification in HRCT and histopathology. Case 1 – a: Common histopathological features of UIP/IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant. HE 100×. Case 1 – b: The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces. HE 100×. Case 1 – c: The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells, either fibroblasts or miofibroblasts, with collagen deposition. Elastin-van Gieson 100×. Case 2 – a: Irregular confluent air spaces with typical subpleural localization of UIP/IPF honeycombing with interstitium enlargement by fusiform cells. HE 100×. Case 2 – b: The adjacent lobular parenchyma accentuate histopathological heterogeneity, starting by overinflation and pseudo emphysema morphology. HE 100×. Case 2 – c: The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization. HE 100×. Case 3 – a: Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix; lymphocytes are seen. PAS 200×. Case 3 – b: UIP/IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule. HE 100×." ] ] 7 => array:6 [ "identificador" => "fig8" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "descripcion" => array:1 [ "en" => "UIP/IPF identification in HRCT and histopathology. Case 1 – a: Common histopathological features of UIP/IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant. HE 100×. Case 1 – b: The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces. HE 100×. Case 1 – c: The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells, either fibroblasts or miofibroblasts, with collagen deposition. Elastin-van Gieson 100×. Case 2 – a: Irregular confluent air spaces with typical subpleural localization of UIP/IPF honeycombing with interstitium enlargement by fusiform cells. HE 100×. Case 2 – b: The adjacent lobular parenchyma accentuate histopathological heterogeneity, starting by overinflation and pseudo emphysema morphology. HE 100×. Case 2 – c: The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization. HE 100×. Case 3 – a: Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix; lymphocytes are seen. PAS 200×. Case 3 – b: UIP/IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule. HE 100×." ] ] 8 => array:6 [ "identificador" => "fig9" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "descripcion" => array:1 [ "en" => "UIP/IPF identification in HRCT and histopathology. Case 1 – a: Common histopathological features of UIP/IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant. HE 100×. Case 1 – b: The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces. HE 100×. Case 1 – c: The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells, either fibroblasts or miofibroblasts, with collagen deposition. Elastin-van Gieson 100×. Case 2 – a: Irregular confluent air spaces with typical subpleural localization of UIP/IPF honeycombing with interstitium enlargement by fusiform cells. HE 100×. Case 2 – b: The adjacent lobular parenchyma accentuate histopathological heterogeneity, starting by overinflation and pseudo emphysema morphology. HE 100×. Case 2 – c: The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization. HE 100×. Case 3 – a: Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix; lymphocytes are seen. PAS 200×. Case 3 – b: UIP/IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule. HE 100×." ] ] 9 => array:6 [ "identificador" => "fig10" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "descripcion" => array:1 [ "en" => "Idiopathic pulmonary fibrosis patient flow. HRCT: high-resolution computed tomography." ] ] ] "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:95 [ 0 => array:3 [ "identificador" => "bib96" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183:788-824." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.2009-040GL" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med. " "fecha" => "2011" "volumen" => "183" "paginaInicial" => "788" "paginaFinal" => "824" "link" => array:1 [ …1] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib97" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Idiopathic pulmonary fibrosis. Lancet. 2011; 378:1949-61." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(11)60052-4" "Revista" => array:6 [ "tituloSerie" => "Lancet. " "fecha" => "2011" "volumen" => "378" "paginaInicial" => "1949" "paginaFinal" => "1961" "link" => array:1 [ …1] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib98" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines. Eur Respir Rev. 2014; 23:193-214." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09059180.00001814" "Revista" => array:6 [ "tituloSerie" => "Eur Respir Rev. " "fecha" => "2014" "volumen" => "23" "paginaInicial" => "193" "paginaFinal" => "214" "link" => array:1 [ …1] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib99" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Idiopathic pulmonary fibrosis: evolving concepts. Mayo Clin Proc. 2014; 89:1130-42." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Idiopathic pulmonary fibrosis: evolving concepts." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.mayocp.2014.03.016" "Revista" => array:6 [ "tituloSerie" => "Mayo Clin Proc. " "fecha" => "2014" "volumen" => "89" "paginaInicial" => "1130" "paginaFinal" => "1142" "link" => array:1 [ …1] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib100" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Why do patients get idiopathic pulmonary fibrosis? Current concepts in the pathogenesis of pulmonary fibrosis. BMC Med. 2015; 13:176." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Why do patients get idiopathic pulmonary fibrosis? Current concepts in the pathogenesis of pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s12916-015-0412-6" "Revista" => array:5 [ "tituloSerie" => "BMC Med. " "fecha" => "2015" "volumen" => "13" "paginaInicial" => "176" "link" => array:1 [ …1] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib101" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000; 161:646-64." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/ajrccm.161.2.ats3-00" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med. " "fecha" => "2000" "volumen" => "161" "paginaInicial" => "646" "paginaFinal" => "664" "link" => array:1 [ …1] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib102" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy. Pharmacol Ther. 2015. pii:S0163-7258(15)00091-1" "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.pharmthera.2007.04.009" "Revista" => array:3 [ "tituloSerie" => "Pharmacol Ther. " "fecha" => "2015" "link" => array:1 [ …1] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib103" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377:1760-9." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(11)60405-4" "Revista" => array:6 [ "tituloSerie" => "Lancet. " "fecha" => "2011" "volumen" => "377" "paginaInicial" => "1760" "paginaFinal" => "1769" "link" => array:1 [ …1] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib104" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011; 365:1079-87." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1103690" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med. " "fecha" => "2011" "volumen" => "365" "paginaInicial" => "1079" "paginaFinal" => "1087" "link" => array:1 [ …1] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib105" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370:2083-92." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1402582" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med. " "fecha" => "2014" "volumen" => "370" "paginaInicial" => "2083" "paginaFinal" => "2092" "link" => array:1 [ …1] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib106" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370:2071-82." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1402584" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med. " "fecha" => "2014" "volumen" => "370" "paginaInicial" => "2071" "paginaFinal" => "2082" "link" => array:1 [ …1] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib107" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Programa Nacional para as Doenças Respiratórias. Direcção-Geral da Saúde. 2012 September 05." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Programa Nacional para as Doenças Respiratórias. Direcção-Geral da Saúde." "idioma" => "pt" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:2 [ "titulo" => "Programa Nacional para as Doenças Respiratórias. Direcção-Geral da Saúde." "fecha" => "2012 September 05" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib108" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Research Group on Diffuse Pulmonary Diseases. Arch Bronconeumol. 2013; 49:343-53." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Research Group on Diffuse Pulmonary Diseases." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.arbres.2013.03.011" "Revista" => array:6 [ "tituloSerie" => "Arch Bronconeumol. " "fecha" => "2013" "volumen" => "49" "paginaInicial" => "343" "paginaFinal" => "353" "link" => array:1 [ …1] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib109" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012; 21:355-61." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09059180.00002512" "Revista" => array:6 [ "tituloSerie" => "Eur Respir Rev. " "fecha" => "2012" "volumen" => "21" "paginaInicial" => "355" "paginaFinal" => "361" "link" => array:1 [ …1] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib110" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol. 2013; 5:483-92." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Epidemiology of idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2147/CLEP.S54815" "Revista" => array:6 [ "tituloSerie" => "Clin Epidemiol. " "fecha" => "2013" "volumen" => "5" "paginaInicial" => "483" "paginaFinal" => "492" "link" => array:1 [ …1] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib111" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002; 165:277-304." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/ajrccm.165.2.ats01" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med. " "fecha" => "2002" "volumen" => "165" "paginaInicial" => "277" "paginaFinal" => "304" "link" => array:1 [ …1] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib112" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Idiopathic pulmonary fibrosis-clinical presentation, outcome and baseline prognostic factors in a Portuguese cohort. Rev Port Pneumol. 2013; 19:19-27." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Idiopathic pulmonary fibrosis-clinical presentation, outcome and baseline prognostic factors in a Portuguese cohort." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.rppneu.2012.05.002" "Revista" => array:6 [ "tituloSerie" => "Rev Port Pneumol. " "fecha" => "2013" "volumen" => "19" "paginaInicial" => "19" "paginaFinal" => "27" "link" => array:1 [ …1] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib113" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Idiopathic pulmonary fibrosis: diagnosis and prognostic evaluation. Respiration. 2013; 86:5-12." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Idiopathic pulmonary fibrosis: diagnosis and prognostic evaluation." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000353580" "Revista" => array:6 [ "tituloSerie" => "Respiration. " "fecha" => "2013" "volumen" => "86" "paginaInicial" => "5" "paginaFinal" => "12" "link" => array:1 [ …1] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib114" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "The genetic and environmental causes of pulmonary fibrosis. Proc Am Thorac Soc. 2012; 9:120-5." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "The genetic and environmental causes of pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1513/pats.201112-055AW" "Revista" => array:6 [ "tituloSerie" => "Proc Am Thorac Soc. " "fecha" => "2012" "volumen" => "9" "paginaInicial" => "120" "paginaFinal" => "125" "link" => array:1 [ …1] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib115" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007; 356:1317-26." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Telomerase mutations in families with idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa066157" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med. " "fecha" => "2007" "volumen" => "356" "paginaInicial" => "1317" "paginaFinal" => "1326" "link" => array:1 [ …1] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib116" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Telomerase and telomere length in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2013; 49:260-8." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Telomerase and telomere length in pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1165/rcmb.2012-0514OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Cell Mol Biol. " "fecha" => "2013" "volumen" => "49" "paginaInicial" => "260" "paginaFinal" => "268" "link" => array:1 [ …1] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib117" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011; 364:1503-12." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "A common MUC5B promoter polymorphism and pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1013660" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med. " "fecha" => "2011" "volumen" => "364" "paginaInicial" => "1503" "paginaFinal" => "1512" "link" => array:1 [ …1] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib118" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PLoS ONE. 2013; 8:e70621." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0070621" "Revista" => array:5 [ "tituloSerie" => "PLoS ONE. " "fecha" => "2013" "volumen" => "8" "paginaInicial" => "e70621" "link" => array:1 [ …1] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib119" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006; 27:136-42." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.06.00037005" "Revista" => array:6 [ "tituloSerie" => "Eur Respir J. " "fecha" => "2006" "volumen" => "27" "paginaInicial" => "136" "paginaFinal" => "142" "link" => array:1 [ …1] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib120" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomized controlled trials. Lancet Respir Med. 2013; 1:369-76." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomized controlled trials." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S2213-2600(13)70105-X" "Revista" => array:6 [ "tituloSerie" => "Lancet Respir Med. " "fecha" => "2013" "volumen" => "1" "paginaInicial" => "369" "paginaFinal" => "376" "link" => array:1 [ …1] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib121" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir Rev. 2013; 22:376-81." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "The role of infection in the pathogenesis of idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09059180.00000713" "Revista" => array:6 [ "tituloSerie" => "Eur Respir Rev. " "fecha" => "2013" "volumen" => "22" "paginaInicial" => "376" "paginaFinal" => "381" "link" => array:1 [ …1] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib122" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Viral infection and aging as cofactors for the development of pulmonary fibrosis. Expert Rev Respir Med. 2010; 4:759-71." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Viral infection and aging as cofactors for the development of pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1586/ers.10.73" "Revista" => array:6 [ "tituloSerie" => "Expert Rev Respir Med. " "fecha" => "2010" "volumen" => "4" "paginaInicial" => "759" "paginaFinal" => "771" "link" => array:1 [ …1] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib123" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Approach to the diagnosis of interstitial lung disease. Clin Chest Med. 2012; 33:1-10." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Approach to the diagnosis of interstitial lung disease." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ccm.2011.12.002" "Revista" => array:6 [ "tituloSerie" => "Clin Chest Med. " "fecha" => "2012" "volumen" => "33" "paginaInicial" => "1" "paginaFinal" => "10" "link" => array:1 [ …1] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib124" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Diagnosis of interstitial lung diseases. Mayo Clin Proc. 2007; 82:976-86." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Diagnosis of interstitial lung diseases." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4065/82.8.976" "Revista" => array:6 [ "tituloSerie" => "Mayo Clin Proc. " "fecha" => "2007" "volumen" => "82" "paginaInicial" => "976" "paginaFinal" => "986" "link" => array:1 [ …1] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib125" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "British Thoracic Society Standards of Care Committee; Thoracic Society of Australia; New Zealand Thoracic Society; Irish Thoracic Society. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008; 63(Suppl 5):v1-v58." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "British Thoracic Society Standards of Care Committee; Thoracic Society of Australia; New Zealand Thoracic Society; Irish Thoracic Society. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/thx.2008.101691" "Revista" => array:6 [ "tituloSerie" => "Thorax. " "fecha" => "2008" "volumen" => "63" "paginaInicial" => "v1" "paginaFinal" => "v58" "link" => array:1 [ …1] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib126" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Diagnosis and management of interstitial lung disease. Transl Respir Med. 2014; 2:4." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Diagnosis and management of interstitial lung disease." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/2213-0802-2-4" "Revista" => array:5 [ "tituloSerie" => "Transl Respir Med. " "fecha" => "2014" "volumen" => "2" "paginaInicial" => "4" "link" => array:1 [ …1] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib127" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and Adjudication Processes. Chest. 2015; 148:1034-42." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and Adjudication Processes." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1378/chest.14-2889" "Revista" => array:6 [ "tituloSerie" => "Chest. " "fecha" => "2015" "volumen" => "148" "paginaInicial" => "1034" "paginaFinal" => "1042" "link" => array:1 [ …1] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib128" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "The multidisciplinary approach in the diagnosis of idiopathic pulmonary fibrosis: a patient case-based review. Eur Respir Rev. 2015; 24:69-77." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "The multidisciplinary approach in the diagnosis of idiopathic pulmonary fibrosis: a patient case-based review." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09059180.00011714" "Revista" => array:6 [ "tituloSerie" => "Eur Respir Rev. " "fecha" => "2015" "volumen" => "24" "paginaInicial" => "69" "paginaFinal" => "77" "link" => array:1 [ …1] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib129" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?. Eur Respir Rev. 2014; 23:308-19." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09059180.00004914" "Revista" => array:6 [ "tituloSerie" => "Eur Respir Rev. " "fecha" => "2014" "volumen" => "23" "paginaInicial" => "308" "paginaFinal" => "319" "link" => array:1 [ …1] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib130" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. 2012; 186:314-24." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Hypersensitivity pneumonitis: insights in diagnosis and pathobiology." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201203-0513CI" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med. " "fecha" => "2012" "volumen" => "186" "paginaInicial" => "314" "paginaFinal" => "324" "link" => array:1 [ …1] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib131" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012; 185:1004-14." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201202-0320ST" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med. " "fecha" => "2012" "volumen" => "185" "paginaInicial" => "1004" "paginaFinal" => "1014" "link" => array:1 [ …1] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib132" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009; 179:1043-7." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.200808-1313OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med. " "fecha" => "2009" "volumen" => "179" "paginaInicial" => "1043" "paginaFinal" => "1047" "link" => array:1 [ …1] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib133" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Bronchoalveolar lavage in other interstitial lung diseases. Semin Respir Crit Care Med. 2007; 28:514-24." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Bronchoalveolar lavage in other interstitial lung diseases." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1055/s-2007-991525" "Revista" => array:6 [ "tituloSerie" => "Semin Respir Crit Care Med. " "fecha" => "2007" "volumen" => "28" "paginaInicial" => "514" "paginaFinal" => "524" "link" => array:1 [ …1] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib134" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "The clinical utility of bronchoalveolar lavage in diffuse parenchymal lung disease. Eur Respir Rev. 2010; 19:237-41." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "The clinical utility of bronchoalveolar lavage in diffuse parenchymal lung disease." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09059180.00005510" "Revista" => array:6 [ "tituloSerie" => "Eur Respir Rev. " "fecha" => "2010" "volumen" => "19" "paginaInicial" => "237" "paginaFinal" => "241" "link" => array:1 [ …1] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib135" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "The role of transbronchial biopsy in the diagnosis of diffuse parenchymal lung diseases: con. Rev Port Pneumol. 2012; 18:61-3." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "The role of transbronchial biopsy in the diagnosis of diffuse parenchymal lung diseases: con." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.rppneu.2011.09.004" "Revista" => array:6 [ "tituloSerie" => "Rev Port Pneumol. " "fecha" => "2012" "volumen" => "18" "paginaInicial" => "61" "paginaFinal" => "63" "link" => array:1 [ …1] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib136" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Lung cryobiopsies: a paradigm shift in diagnostic bronchoscopy?. Respirology. 2014; 19:645-54." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Lung cryobiopsies: a paradigm shift in diagnostic bronchoscopy?." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/resp.12309" "Revista" => array:6 [ "tituloSerie" => "Respirology. " "fecha" => "2014" "volumen" => "19" "paginaInicial" => "645" "paginaFinal" => "654" "link" => array:1 [ …1] ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib137" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS ONE. 2014; 9:e86716." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0086716" "Revista" => array:5 [ "tituloSerie" => "PLoS ONE. " "fecha" => "2014" "volumen" => "9" "paginaInicial" => "e86716" "link" => array:1 [ …1] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib138" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2015. [Epub ahead of print]" "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.200904-0493OC" "Revista" => array:3 [ "tituloSerie" => "Am J Respir Crit Care Med. " "fecha" => "2015" "link" => array:1 [ …1] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib139" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008; 246:697-722." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Fleischner Society: glossary of terms for thoracic imaging." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1148/radiol.2462070712" "Revista" => array:6 [ "tituloSerie" => "Radiology. " "fecha" => "2008" "volumen" => "246" "paginaInicial" => "697" "paginaFinal" => "722" "link" => array:1 [ …1] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib140" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality. Eur Radiol. 2011; 21:1586-93." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00330-011-2098-2" "Revista" => array:6 [ "tituloSerie" => "Eur Radiol. " "fecha" => "2011" "volumen" => "21" "paginaInicial" => "1586" "paginaFinal" => "1593" "link" => array:1 [ …1] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib141" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Idiopathic interstitial pneumonias: a radiology-pathology correlation based on the revised 2013 American Thoracic Society-European Respiratory Society classification system. Curr Probl Diagn Radiol. 2015; 44:15-25." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Idiopathic interstitial pneumonias: a radiology-pathology correlation based on the revised 2013 American Thoracic Society-European Respiratory Society classification system." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1067/j.cpradiol.2014.07.005" "Revista" => array:6 [ "tituloSerie" => "Curr Probl Diagn Radiol. " "fecha" => "2015" "volumen" => "44" "paginaInicial" => "15" "paginaFinal" => "25" "link" => array:1 [ …1] ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib142" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society. Lancet Respir Med. 2015; 3:483-96." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S2213-2600(15)00096-X" "Revista" => array:6 [ "tituloSerie" => "Lancet Respir Med. " "fecha" => "2015" "volumen" => "3" "paginaInicial" => "483" "paginaFinal" => "496" "link" => array:1 [ …1] ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib143" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "distinguish hypersensitivity pneumonitis from idiopathic pulmonary fibrosis?. AJR Am J Roentgenol. 1995; 165:807-11." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "distinguish hypersensitivity pneumonitis from idiopathic pulmonary fibrosis?." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2214/ajr.165.4.7676971" "Revista" => array:6 [ "tituloSerie" => "AJR Am J Roentgenol. " "fecha" => "1995" "volumen" => "165" "paginaInicial" => "807" "paginaFinal" => "811" "link" => array:1 [ …1] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib144" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Fibrosing interstitial lung disease. A practical high-resolution computed tomography-based approach to diagnosis and management and a review of the literature. Am J Respir Crit Care Med. 2013; 188:141-9." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Fibrosing interstitial lung disease. A practical high-resolution computed tomography-based approach to diagnosis and management and a review of the literature." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201208-1544CI" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med. " "fecha" => "2013" "volumen" => "188" "paginaInicial" => "141" "paginaFinal" => "149" "link" => array:1 [ …1] ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib145" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005; 172:488-93." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.200412-1756OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med. " "fecha" => "2005" "volumen" => "172" "paginaInicial" => "488" "paginaFinal" => "493" "link" => array:1 [ …1] ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib146" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Update for pathologists on idiopathic interstitial pneumonias. Arch Pathol Lab Med. 2012; 136:1234-41." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Update for pathologists on idiopathic interstitial pneumonias." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.5858/arpa.2012-0225-RA" "Revista" => array:6 [ "tituloSerie" => "Arch Pathol Lab Med. " "fecha" => "2012" "volumen" => "136" "paginaInicial" => "1234" "paginaFinal" => "1241" "link" => array:1 [ …1] ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib147" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015; 192:e3-e19." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201506-1063ST" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med. " "fecha" => "2015" "volumen" => "192" "paginaInicial" => "e3" "paginaFinal" => "e19" "link" => array:1 [ …1] ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib148" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Comparing new treatments for idiopathic pulmonary fibrosis – a network meta-analysis. BMC Pulm Med. 2015; 15:37." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Comparing new treatments for idiopathic pulmonary fibrosis – a network meta-analysis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s12890-015-0034-y" "Revista" => array:5 [ "tituloSerie" => "BMC Pulm Med. " "fecha" => "2015" "volumen" => "15" "paginaInicial" => "37" "link" => array:1 [ …1] ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib149" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag. 2015; 11:359-70." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Update on therapeutic management of idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2147/TCRM.S69716" "Revista" => array:6 [ "tituloSerie" => "Ther Clin Risk Manag. " "fecha" => "2015" "volumen" => "11" "paginaInicial" => "359" "paginaFinal" => "370" "link" => array:1 [ …1] ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib150" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Summary of Product Characteristics: Ofev. 2015 May. Available from: <inter-ref>http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/003821/WC500182474.pdf</inter-ref>" "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Summary of Product Characteristics: Ofev." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:2 [ "titulo" => "Summary of Product Characteristics: Ofev." "fecha" => "2015 May" ] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib151" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001; 134:136-51." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Intern Med. " "fecha" => "2001" "volumen" => "134" "paginaInicial" => "136" "paginaFinal" => "151" "link" => array:1 [ …1] ] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib152" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008; 68:4774-82." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1158/0008-5472.CAN-07-6307" "Revista" => array:6 [ "tituloSerie" => "Cancer Res. " "fecha" => "2008" "volumen" => "68" "paginaInicial" => "4774" "paginaFinal" => "4782" "link" => array:1 [ …1] ] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib153" "etiqueta" => "58" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011; 37:356-63." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.00159709" "Revista" => array:6 [ "tituloSerie" => "Eur Respir J. " "fecha" => "2011" "volumen" => "37" "paginaInicial" => "356" "paginaFinal" => "363" "link" => array:1 [ …1] ] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib154" "etiqueta" => "59" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Nintedanib: a new treatment for idiopathic pulmonary fibrosis. Clin Invest. 2015; 5:621-32." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Nintedanib: a new treatment for idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Invest. " "fecha" => "2015" "volumen" => "5" "paginaInicial" => "621" "paginaFinal" => "632" ] ] ] ] ] ] 59 => array:3 [ "identificador" => "bib155" "etiqueta" => "60" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Summary of Product Characteristics: Esbriet. 2015 May. Available from: <inter-ref>http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/002154/WC500103049.pdf</inter-ref>" "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Summary of Product Characteristics: Esbriet." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:2 [ "titulo" => "Summary of Product Characteristics: Esbriet." "fecha" => "2015 May" ] ] ] ] ] ] 60 => array:3 [ "identificador" => "bib156" "etiqueta" => "61" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016; 47:243-53." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/13993003.00026-2015" "Revista" => array:6 [ "tituloSerie" => "Eur Respir J. " "fecha" => "2016" "volumen" => "47" "paginaInicial" => "243" "paginaFinal" => "253" "link" => array:1 [ …1] ] ] ] ] ] ] 61 => array:3 [ "identificador" => "bib157" "etiqueta" => "62" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005; 171:1040-7." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.200404-571OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med. " "fecha" => "2005" "volumen" => "171" "paginaInicial" => "1040" "paginaFinal" => "1047" "link" => array:1 [ …1] ] ] ] ] ] ] 62 => array:3 [ "identificador" => "bib158" "etiqueta" => "63" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010; 35:821-9." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Pirfenidone in idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.00005209" "Revista" => array:6 [ "tituloSerie" => "Eur Respir J. " "fecha" => "2010" "volumen" => "35" "paginaInicial" => "821" "paginaFinal" => "829" "link" => array:1 [ …1] ] ] ] ] ] ] 63 => array:3 [ "identificador" => "bib159" "etiqueta" => "64" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015; 24:58-64." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09059180.00011514" "Revista" => array:6 [ "tituloSerie" => "Eur Respir Rev. " "fecha" => "2015" "volumen" => "24" "paginaInicial" => "58" "paginaFinal" => "64" "link" => array:1 [ …1] ] ] ] ] ] ] 64 => array:3 [ "identificador" => "bib160" "etiqueta" => "65" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib. Drug Des Dev Ther. 2015; 9:6407-19." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Drug Des Dev Ther. " "fecha" => "2015" "volumen" => "9" "paginaInicial" => "6407" "paginaFinal" => "6419" ] ] ] ] ] ] 65 => array:3 [ "identificador" => "bib161" "etiqueta" => "66" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005; 353:2229-42." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "High-dose acetylcysteine in idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa042976" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med. " "fecha" => "2005" "volumen" => "353" "paginaInicial" => "2229" "paginaFinal" => "2242" "link" => array:1 [ …1] ] ] ] ] ] ] 66 => array:3 [ "identificador" => "bib162" "etiqueta" => "67" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012; 366:1968-77." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1113354" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med. " "fecha" => "2012" "volumen" => "366" "paginaInicial" => "1968" "paginaFinal" => "1977" "link" => array:1 [ …1] ] ] ] ] ] ] 67 => array:3 [ "identificador" => "bib163" "etiqueta" => "68" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370:2093-101." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1401739" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med. " "fecha" => "2014" "volumen" => "370" "paginaInicial" => "2093" "paginaFinal" => "2101" "link" => array:1 [ …1] ] ] ] ] ] ] 68 => array:3 [ "identificador" => "bib164" "etiqueta" => "69" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010; 181:604-10." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.200906-0964OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med. " "fecha" => "2010" "volumen" => "181" "paginaInicial" => "604" "paginaFinal" => "610" "link" => array:1 [ …1] ] ] ] ] ] ] 69 => array:3 [ "identificador" => "bib165" "etiqueta" => "70" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest. 2005; 128:1475-82." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Anticoagulant therapy for idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1378/chest.128.3.1475" "Revista" => array:6 [ "tituloSerie" => "Chest. " "fecha" => "2005" "volumen" => "128" "paginaInicial" => "1475" "paginaFinal" => "1482" "link" => array:1 [ …1] ] ] ] ] ] ] 70 => array:3 [ "identificador" => "bib166" "etiqueta" => "71" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012; 186:88-95." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201202-0314OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med. " "fecha" => "2012" "volumen" => "186" "paginaInicial" => "88" "paginaFinal" => "95" "link" => array:1 [ …1] ] ] ] ] ] ] 71 => array:3 [ "identificador" => "bib167" "etiqueta" => "72" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 1999; 341:1264-9." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJM199910213411703" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med. " "fecha" => "1999" "volumen" => "341" "paginaInicial" => "1264" "paginaFinal" => "1269" "link" => array:1 [ …1] ] ] ] ] ] ] 72 => array:3 [ "identificador" => "bib168" "etiqueta" => "73" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004; 350:125-33." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa030511" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med. " "fecha" => "2004" "volumen" => "350" "paginaInicial" => "125" "paginaFinal" => "133" "link" => array:1 [ …1] ] ] ] ] ] ] 73 => array:3 [ "identificador" => "bib169" "etiqueta" => "74" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009; 374:222-8." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(09)60551-1" "Revista" => array:6 [ "tituloSerie" => "Lancet. " "fecha" => "2009" "volumen" => "374" "paginaInicial" => "222" "paginaFinal" => "228" "link" => array:1 [ …1] ] ] ] ] ] ] 74 => array:3 [ "identificador" => "bib170" "etiqueta" => "75" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med. 2008; 178:948-55." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.200709-1446OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med. " "fecha" => "2008" "volumen" => "178" "paginaInicial" => "948" "paginaFinal" => "955" "link" => array:1 [ …1] ] ] ] ] ] ] 75 => array:3 [ "identificador" => "bib171" "etiqueta" => "76" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008; 177:75-81." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.200705-732OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med. " "fecha" => "2008" "volumen" => "177" "paginaInicial" => "75" "paginaFinal" => "81" "link" => array:1 [ …1] ] ] ] ] ] ] 76 => array:3 [ "identificador" => "bib172" "etiqueta" => "77" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 184:92-9." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201011-1874OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med. " "fecha" => "2011" "volumen" => "184" "paginaInicial" => "92" "paginaFinal" => "99" "link" => array:1 [ …1] ] ] ] ] ] ] 77 => array:3 [ "identificador" => "bib173" "etiqueta" => "78" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J. 2013; 42:1622-32." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.00104612" "Revista" => array:6 [ "tituloSerie" => "Eur Respir J. " "fecha" => "2013" "volumen" => "42" "paginaInicial" => "1622" "paginaFinal" => "1632" "link" => array:1 [ …1] ] ] ] ] ] ] 78 => array:3 [ "identificador" => "bib174" "etiqueta" => "79" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013; 158:641-9." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7326/0003-4819-158-9-201305070-00003" "Revista" => array:6 [ "tituloSerie" => "Ann Intern Med. " "fecha" => "2013" "volumen" => "158" "paginaInicial" => "641" "paginaFinal" => "649" "link" => array:1 [ …1] ] ] ] ] ] ] 79 => array:3 [ "identificador" => "bib175" "etiqueta" => "80" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010; 363:620-8." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1002110" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med. " "fecha" => "2010" "volumen" => "363" "paginaInicial" => "620" "paginaFinal" => "628" "link" => array:1 [ …1] ] ] ] ] ] ] 80 => array:3 [ "identificador" => "bib176" "etiqueta" => "81" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 184:1390-4." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201101-0138OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med. " "fecha" => "2011" "volumen" => "184" "paginaInicial" => "1390" "paginaFinal" => "1394" "link" => array:1 [ …1] ] ] ] ] ] ] 81 => array:3 [ "identificador" => "bib177" "etiqueta" => "82" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "British Thoracic Society guideline on pulmonary rehabilitation in adults. Thorax. 2013; 689(Suppl 2):ii1-ii30." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "British Thoracic Society guideline on pulmonary rehabilitation in adults." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Thorax. " "fecha" => "2013" "volumen" => "689" "paginaInicial" => "ii1" "paginaFinal" => "ii30" ] ] ] ] ] ] 82 => array:3 [ "identificador" => "bib178" "etiqueta" => "83" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Physical Activity and Quality of Life Improvements of Patients with Idiopathic Pulmonary Fibrosis Completing a Pulmonary Rehabilitation Program. Respir Care. 2014; 59:1-8." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Physical Activity and Quality of Life Improvements of Patients with Idiopathic Pulmonary Fibrosis Completing a Pulmonary Rehabilitation Program." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Respir Care. " "fecha" => "2014" "volumen" => "59" "paginaInicial" => "1" "paginaFinal" => "8" ] ] ] ] ] ] 83 => array:3 [ "identificador" => "bib179" "etiqueta" => "84" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "International guidelines for the selection of lung transplant candidates: 2006 update – a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006; 25:745-55." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "International guidelines for the selection of lung transplant candidates: 2006 update – a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.healun.2006.03.011" "Revista" => array:6 [ "tituloSerie" => "J Heart Lung Transplant. " "fecha" => "2006" "volumen" => "25" "paginaInicial" => "745" "paginaFinal" => "755" "link" => array:1 [ …1] ] ] ] ] ] ] 84 => array:3 [ "identificador" => "bib180" "etiqueta" => "85" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant Proc. 2009; 41:289-91." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.transproceed.2008.10.042" "Revista" => array:6 [ "tituloSerie" => "Transplant Proc. " "fecha" => "2009" "volumen" => "41" "paginaInicial" => "289" "paginaFinal" => "291" "link" => array:1 [ …1] ] ] ] ] ] ] 85 => array:3 [ "identificador" => "bib181" "etiqueta" => "86" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review. Intern Emerg Med. 2015. [Epub ahead of print]" "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Intern Emerg Med. " "fecha" => "2015" ] ] ] ] ] ] 86 => array:3 [ "identificador" => "bib182" "etiqueta" => "87" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies. J Thorac Dis. 2015; 7:499-519." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3978/j.issn.2072-1439.2015.01.17" "Revista" => array:6 [ "tituloSerie" => "J Thorac Dis. " "fecha" => "2015" "volumen" => "7" …3 ] ] ] ] ] ] 87 => array:3 [ "identificador" => "bib183" "etiqueta" => "88" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "The role of gastroesophageal reflux and microaspiration in idiopathic pulmonary fibrosis. Clin Pulm Med. 2014; 21:81-5." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "The role of gastroesophageal reflux and microaspiration in idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 88 => array:3 [ "identificador" => "bib184" "etiqueta" => "89" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol. 2006; 44:372-6." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease." "idioma" => "en" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.vph.2006.01.013" "Revista" => array:6 [ …6] ] ] ] ] ] 89 => array:3 [ "identificador" => "bib185" "etiqueta" => "90" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007; 131:897-9." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Sildenafil improves walk distance in idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1378/chest.06-2101" "Revista" => array:6 [ …6] ] ] ] ] ] 90 => array:3 [ "identificador" => "bib186" "etiqueta" => "91" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest. 2013; 143:1699-708." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction." "idioma" => "en" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1378/chest.12-1594" "Revista" => array:6 [ …6] ] ] ] ] ] 91 => array:3 [ "identificador" => "bib187" "etiqueta" => "92" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "ARTEMIS-IPF: a placebo-controlled trial of ambrisentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012; 185:A3632." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "ARTEMIS-IPF: a placebo-controlled trial of ambrisentan in idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ …4] ] ] ] ] ] 92 => array:3 [ "identificador" => "bib188" "etiqueta" => "93" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "The palliative care needs for fibrotic interstitial lung disease: a qualitative study of patients, informal caregivers and health professionals. Palliat Med. 2013; 27:869-76." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "The palliative care needs for fibrotic interstitial lung disease: a qualitative study of patients, informal caregivers and health professionals." "idioma" => "en" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/0269216313497226" "Revista" => array:6 [ …6] ] ] ] ] ] 93 => array:3 [ "identificador" => "bib189" "etiqueta" => "94" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Palliative medicine and end-of-life care in idiopathic pulmonary fibrosis. J Palliat Med. 2013; 16:339." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Palliative medicine and end-of-life care in idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1089/jpm.2012.0531" "Revista" => array:5 [ …5] ] ] ] ] ] 94 => array:3 [ "identificador" => "bib190" "etiqueta" => "95" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Palliative care and location of death in decedents with idiopathic pulmonary fibrosis. Chest. 2015; 147:423-9." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Palliative care and location of death in decedents with idiopathic pulmonary fibrosis." "idioma" => "en" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1378/chest.14-1127" "Revista" => array:6 [ …6] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/08732159/0000002200000002/v0_201604141122/X0873215916514648/v0_201604141122/en/main.assets" "Apartado" => array:4 [ "identificador" => "50813" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Consensus" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/08732159/0000002200000002/v0_201604141122/X0873215916514648/v0_201604141122/en/320v22n02a90451464pdf001.pdf?idApp=UINPBA00004E&text.app=https://journalpulmonology.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0873215916514648?idApp=UINPBA00004E"]

Statistics

C.. Robalo Cordeiroa,

Corresponding author

carlos.crobalo@gmail.com

Corresponding author. carlos.crobalo@gmail.com

, P.. Camposb, L.. Carvalhoc, S.. Campainhad, S.. Clementee, L.. Figueiredof, J.M.. Jesusg, A.. Marquesh, C.. Souto-Mourai, R.. Pinto Bastoj, A.. Ribeirok, M.. Serradoj, A.. Moraish

a Centre of Pulmonology, Coimbra University Hospital, Coimbra, Portugal

b Imagiology Department, Santa Marta Hospital, Northern Lisbon Hospital Centre, Lisbon, Portugal

c Anatomical Pathology Institute, Faculty of Medicine of the University of Coimbra, Coimbra, Portugal

d Pulmonology Department, Vila Nova de Gaia/Espinho Hospital Centre, Vila Nova de Gaia, Portugal

e Pulmonology Department, Beatriz Ângelo Hospital, Loures, Portugal

f Radiology Department, Santa Marta Hospital, Central Lisbon Hospital Centre, Lisbon, Portugal

g Radiology Department, São João Hospital Centre, Oporto, Portugal

h Pulmonology Department, São João Hospital Centre, Faculty of Medicine of Porto University, Oporto, Portugal

i Pathology Department, São João Hospital Centre, Faculty of Medicine of Porto University, Oporto, Portugal

j Pulmonology II Department, Pulido Valente Hospital, Northern Lisbon Hospital Centre, Lisbon, Portugal

k Anatomical Pathology Department, Pulido Valente Hospital, Northern Lisbon Hospital Centre, Lisbon, Portugal

Read

2888

Times
was read the article

849

Total PDF

2039

Total HTML

Share statistics

 array:21 [
  "pii" => "X0873215916514648"
  "issn" => "08732159"
  "doi" => "10.1016/j.rppnen.2016.01.003"
  "estado" => "S300"
  "fechaPublicacion" => "2016-03-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Rev Port Pneumol. 2016;22:112-22"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 880
    "formatos" => array:2 [
      "HTML" => 658
      "PDF" => 222
    ]
  ]
  "itemSiguiente" => array:16 [
    "pii" => "X0873215916514656"
    "issn" => "08732159"
    "doi" => "10.1016/j.rppnen.2015.09.005"
    "estado" => "S300"
    "fechaPublicacion" => "2016-03-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Rev Port Pneumol. 2016;22:123-5"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 376
      "formatos" => array:2 [
        "HTML" => 256
        "PDF" => 120
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Adjuvant chemotherapy in stage IB non-small cell lung carcinoma&#58; A survival analysis"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "123"
          "paginaFinal" => "125"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "D. Coutinho, A. Gon&#231;alves, A. Antunes, S. Campainha, J. Miranda, A. Barroso"
          "autores" => array:6 [
            0 => array:2 [
              "Iniciales" => "D."
              "apellidos" => "Coutinho"
            ]
            1 => array:2 [
              "Iniciales" => "A."
              "apellidos" => "Gon&#231;alves"
            ]
            2 => array:2 [
              "Iniciales" => "A."
              "apellidos" => "Antunes"
            ]
            3 => array:2 [
              "Iniciales" => "S."
              "apellidos" => "Campainha"
            ]
            4 => array:2 [
              "Iniciales" => "J."
              "apellidos" => "Miranda"
            ]
            5 => array:2 [
              "Iniciales" => "A."
              "apellidos" => "Barroso"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0873215916514656?idApp=UINPBA00004E"
    "url" => "/08732159/0000002200000002/v0_201604141122/X0873215916514656/v0_201604141122/en/main.assets"
  ]
  "itemAnterior" => array:16 [
    "pii" => "X087321591651463X"
    "issn" => "08732159"
    "doi" => "10.1016/j.rppnen.2015.12.001"
    "estado" => "S300"
    "fechaPublicacion" => "2016-03-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Rev Port Pneumol. 2016;22:101-11"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 533
      "formatos" => array:2 [
        "HTML" => 338
        "PDF" => 195
      ]
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "titulo" => "Understanding COPD&#58; A vision on phenotypes&#44; comorbidities and treatment approach"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "101"
          "paginaFinal" => "111"
        ]
      ]
      "contieneResumen" => array:1 [
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "320v22n02-90451463fig1.jpg"
              "Alto" => 2973
              "Ancho" => 2500
              "Tamanyo" => 1170702
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Proposed most clinically relevant phenotypes&#46;"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "E. Fragoso, S. Andr&#233;, J.P. Boleo-Tom&#233;, V. Areias, J. Munh&#225;, J. Cardoso"
          "autores" => array:6 [
            0 => array:2 [
              "Iniciales" => "E."
              "apellidos" => "Fragoso"
            ]
            1 => array:2 [
              "Iniciales" => "S."
              "apellidos" => "Andr&#233;"
            ]
            2 => array:2 [
              "Iniciales" => "J.P."
              "apellidos" => "Boleo-Tom&#233;"
            ]
            3 => array:2 [
              "Iniciales" => "V."
              "apellidos" => "Areias"
            ]
            4 => array:2 [
              "Iniciales" => "J."
              "apellidos" => "Munh&#225;"
            ]
            5 => array:2 [
              "Iniciales" => "J."
              "apellidos" => "Cardoso"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X087321591651463X?idApp=UINPBA00004E"
    "url" => "/08732159/0000002200000002/v0_201604141122/X087321591651463X/v0_201604141122/en/main.assets"
  ]
  "asociados" => array:1 [
    0 => array:19 [
      "pii" => "S2173511516000440"
      "issn" => "21735115"
      "doi" => "10.1016/j.rppnen.2016.03.001"
      "estado" => "S300"
      "fechaPublicacion" => "2016-03-01"
      "aid" => "1149"
      "copyright" => "Sociedade Portuguesa de Pneumologia"
      "documento" => "simple-article"
      "crossmark" => 1
      "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
      "subdocumento" => "edi"
      "cita" => "Rev Port Pneumol. 2016;22:70-2"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 1670
        "formatos" => array:3 [
          "EPUB" => 211
          "HTML" => 918
          "PDF" => 541
        ]
      ]
      "en" => array:9 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">EDITORIAL</span>"
        "titulo" => "How to handle IPF &#8211; the new Portuguese consensus document"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "70"
            "paginaFinal" => "72"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Ulrich Costabel, Francesco Bonella"
            "autores" => array:2 [
              0 => array:2 [
                "nombre" => "Ulrich"
                "apellidos" => "Costabel"
              ]
              1 => array:2 [
                "nombre" => "Francesco"
                "apellidos" => "Bonella"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173511516000440?idApp=UINPBA00004E"
      "url" => "/21735115/0000002200000002/v2_201704020101/S2173511516000440/v2_201704020101/en/main.assets"
    ]
  ]
  "en" => array:14 [
    "idiomaDefecto" => true
    "titulo" => "Consensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "112"
        "paginaFinal" => "122"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "C. Robalo Cordeiro, P. Campos, L. Carvalho, S. Campainha, S. Clemente, L. Figueiredo, J.M. Jesus, A. Marques, C. Souto-Moura, R. Pinto Basto, A. Ribeiro, M. Serrado, A. Morais"
        "autores" => array:13 [
          0 => array:4 [
            "Iniciales" => "C."
            "apellidos" => "Robalo Cordeiro"
            "email" => array:1 [
              0 => "carlos&#46;crobalo&#64;gmail&#46;com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor1"
              ]
            ]
          ]
          1 => array:3 [
            "Iniciales" => "P."
            "apellidos" => "Campos"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          2 => array:3 [
            "Iniciales" => "L."
            "apellidos" => "Carvalho"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          3 => array:3 [
            "Iniciales" => "S."
            "apellidos" => "Campainha"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "affd"
              ]
            ]
          ]
          4 => array:3 [
            "Iniciales" => "S."
            "apellidos" => "Clemente"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "affe"
              ]
            ]
          ]
          5 => array:3 [
            "Iniciales" => "L."
            "apellidos" => "Figueiredo"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "afff"
              ]
            ]
          ]
          6 => array:3 [
            "Iniciales" => "J.M."
            "apellidos" => "Jesus"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "affg"
              ]
            ]
          ]
          7 => array:3 [
            "Iniciales" => "A."
            "apellidos" => "Marques"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "affh"
              ]
            ]
          ]
          8 => array:3 [
            "Iniciales" => "C."
            "apellidos" => "Souto-Moura"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "affi"
              ]
            ]
          ]
          9 => array:3 [
            "Iniciales" => "R."
            "apellidos" => "Pinto Basto"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">j</span>"
                "identificador" => "affj"
              ]
            ]
          ]
          10 => array:3 [
            "Iniciales" => "A."
            "apellidos" => "Ribeiro"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">k</span>"
                "identificador" => "affk"
              ]
            ]
          ]
          11 => array:3 [
            "Iniciales" => "M."
            "apellidos" => "Serrado"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">j</span>"
                "identificador" => "affj"
              ]
            ]
          ]
          12 => array:3 [
            "Iniciales" => "A."
            "apellidos" => "Morais"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "affh"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:11 [
          0 => array:3 [
            "entidad" => "Centre of Pulmonology, Coimbra University Hospital, Coimbra, Portugal"
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => "Imagiology Department, Santa Marta Hospital, Northern Lisbon Hospital Centre, Lisbon, Portugal"
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
          2 => array:3 [
            "entidad" => "Anatomical Pathology Institute, Faculty of Medicine of the University of Coimbra, Coimbra, Portugal"
            "etiqueta" => "<span class="elsevierStyleSup">c</span>"
            "identificador" => "affc"
          ]
          3 => array:3 [
            "entidad" => "Pulmonology Department, Vila Nova de Gaia/Espinho Hospital Centre, Vila Nova de Gaia, Portugal"
            "etiqueta" => "<span class="elsevierStyleSup">d</span>"
            "identificador" => "affd"
          ]
          4 => array:3 [
            "entidad" => "Pulmonology Department, Beatriz Ângelo Hospital, Loures, Portugal"
            "etiqueta" => "<span class="elsevierStyleSup">e</span>"
            "identificador" => "affe"
          ]
          5 => array:3 [
            "entidad" => "Radiology Department, Santa Marta Hospital, Central Lisbon Hospital Centre, Lisbon, Portugal"
            "etiqueta" => "<span class="elsevierStyleSup">f</span>"
            "identificador" => "afff"
          ]
          6 => array:3 [
            "entidad" => "Radiology Department, São João Hospital Centre, Oporto, Portugal"
            "etiqueta" => "<span class="elsevierStyleSup">g</span>"
            "identificador" => "affg"
          ]
          7 => array:3 [
            "entidad" => "Pulmonology Department, São João Hospital Centre, Faculty of Medicine of Porto University, Oporto, Portugal"
            "etiqueta" => "<span class="elsevierStyleSup">h</span>"
            "identificador" => "affh"
          ]
          8 => array:3 [
            "entidad" => "Pathology Department, São João Hospital Centre, Faculty of Medicine of Porto University, Oporto, Portugal"
            "etiqueta" => "<span class="elsevierStyleSup">i</span>"
            "identificador" => "affi"
          ]
          9 => array:3 [
            "entidad" => "Pulmonology II Department, Pulido Valente Hospital, Northern Lisbon Hospital Centre, Lisbon, Portugal"
            "etiqueta" => "<span class="elsevierStyleSup">j</span>"
            "identificador" => "affj"
          ]
          10 => array:3 [
            "entidad" => "Anatomical Pathology Department, Pulido Valente Hospital, Northern Lisbon Hospital Centre, Lisbon, Portugal"
            "etiqueta" => "<span class="elsevierStyleSup">k</span>"
            "identificador" => "affk"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor1"
            "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
            "correspondencia" => "Corresponding author. carlos.crobalo@gmail.com"
          ]
        ]
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "320v22n02-90451464fig1.jpg"
            "Alto" => 2688
            "Ancho" => 2167
            "Tamanyo" => 410222
          ]
        ]
        "descripcion" => array:1 [
          "en" => "IPF diagnosis algorithm&#46; ILD&#58; interstitial lung disease&#59; IPF&#58; idiopathic pulmonary fibrosis&#59; HRCT&#58; high-resolution computed tomography&#59; UIP&#58; usual interstitial pneumonia&#46;"
        ]
      ]
    ]
    "textoCompleto" => "<a name="sec0005" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Introduction</span><p class="elsevierStylePara">Idiopathic pulmonary fibrosis &#40;IPF&#41; is the most common and fatal of the idiopathic interstitial pneumonias subgroup&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib97" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">2</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib98" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">3</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib99" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">4</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib100" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">5</span></a></p><p class="elsevierStylePara">After the first IPF consensus<a href="&#35;bib101" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">6</span></a> of the American Thoracic Society &#40;ATS&#41;&#47;European Respiratory Society &#40;ERS&#41; in 2000&#44; several studies contributed to a greater knowledge of IPF diagnosis and treatment&#44; which was reflected in the updated international consensus on the diagnosis and management of IPF published in 2011 and signed by the American &#40;ATS&#41;&#44; European &#40;ERS&#41;&#44; Japanese &#40;JRS&#41; and Latin American Associations &#40;ALAT&#41;&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a> Since this publication several developments in the IPF management there have been&#44; including diagnostic criteria and therapeutic options&#46;<a href="&#35;bib102" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">7</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib103" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">8</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib104" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">9</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib105" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">10</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib106" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">11</span></a></p><p class="elsevierStylePara">Interstitial lung diseases are identified as priority intervention in the Portuguese National Program of Respiratory Diseases<a href="&#35;bib107" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">12</span></a>&#59; nonetheless there is a general consensus about the need for greater awareness for the identification of these patients&#44; enabling an earlier diagnosis and treatment&#46;</p><a name="sec0010" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Definition</span><p class="elsevierStylePara">IPF is defined as a specific form of chronic&#44; progressive fibrosing interstitial pneumonia of unknown cause&#44; predominantly in adults over 50 years&#44; limited to the lungs&#44; and associated with the radiologic and&#47;or histopathologic pattern of usual interstitial pneumonia &#40;UIP&#41;&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib97" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">2</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib98" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">3</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib108" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">13</span></a></p><a name="sec0015" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Epidemiology</span><p class="elsevierStylePara">Depending on the criteria and methodology adopted in reliable studies&#44;<a href="&#35;bib109" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">14</span></a> IPF incidence ranges between 0&#46;22 and 17&#46;4 per 100&#44;000&#160;person-year&#44; and the prevalence between 14 and 27&#46;9 cases per 100&#44;000 persons&#46; It is unknown if geographic&#44; ethnic&#44; cultural or racial factors influence the incidence and prevalence of IPF&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib110" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">15</span></a> IPF is associated with a poor prognosis&#44; with a median survival of 2&#8211;3 years after the diagnosis&#46;<a href="&#35;bib111" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">16</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib112" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">17</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib113" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">18</span></a></p><a name="sec0020" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Risk factors</span><p class="elsevierStylePara">Although the aetiology of IPF is unknown&#44; several potential risk factors have been identified including&#58; &#40;a&#41; environmental factors like smoking history of &#62;20 packs&#47;year&#44; exposure to silicon&#44; brass&#44; steel&#44; lead and wood dust&#44; farming and agricultural work&#44; construction of wooden houses<a href="&#35;bib114" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">19</span></a>&#59; &#40;b&#41; genetic factors such as familial pulmonary fibrosis&#44; mutations in the genes that maintain the length of the telomeres &#40;TERT &#8211; Telomerase reverse transcriptase&#44; TERC &#8211; Telomerase RNA component&#41;&#44; mutations in the surfactant protein C gene and mutations in the mucin 5B promoter region &#40;MUC5B&#41;<a href="&#35;bib115" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">20</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib116" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">21</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib117" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">22</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib118" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">23</span></a>&#59; &#40;c&#41; gastro-oesophageal reflux &#40;GER&#41;&#44; considered a risk factor for the predisposition and progression of IPF<a href="&#35;bib119" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">24</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib120" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">25</span></a>&#59; &#40;d&#41; viral infections&#44; although there is no sufficient data to state their role in IPF despite the large number of studies analyzing the etiological risk effect of hepatitis C virus&#44; herpes virus and adenovirus<a href="&#35;bib121" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">26</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib122" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">27</span></a>&#59; and &#40;e&#41; autoimmunity&#44; that is still being studied but the possible autoimmune origin of IPF is based on the association of radiologic and&#47;or histologic manifestations of UIP to connective tissue diseases&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib108" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">13</span></a></p><a name="sec0025" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Diagnosis</span><p class="elsevierStylePara">The diagnosis of IPF requires a multidisciplinary approach&#44; including the awareness of general practice physicians&#44; and experienced pulmonologists&#44; radiologists and pathologists in the evaluation and correct treatment of diffuse interstitial lung disease &#40;DILD&#41;&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib98" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">3</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib108" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">13</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib123" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">28</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib124" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">29</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib125" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">30</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib126" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">31</span></a> This approach helps increase diagnostic accuracy and is an internationally accepted recommendation&#46;<a href="&#35;bib123" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">28</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib124" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">29</span></a></p><p class="elsevierStylePara"><a href="&#35;t0005" class="elsevierStyleCrossRefs">Table 1</a> presents the procedures that should be performed at diagnosis&#44; systematically and occasionally&#46;</p><p class="elsevierStylePara">Table 1&#46; Idiopathic pulmonary fibrosis diagnosis examinations&#46;</p><a name="t0005" class="elsevierStyleCrossRefs"></a><p class="elsevierStylePara"></p><table><tr align="left"><td><span class="elsevierStyleBold">At IPF diagnosis</span></td></tr><tr align="left"><td><span class="elsevierStyleItalic">Systematic</span></td></tr><tr align="left"><td>Chest HRCT</td></tr><tr align="left"><td>Plethysmography and DLCO</td></tr><tr align="left"><td>Arterial blood gas in room air at rest</td></tr><tr align="left"><td>6MWT with measurement of percutaneous oxygen saturation</td></tr><tr align="left"><td>Doppler echocardiography</td></tr><tr align="left"><td>&#160;</td></tr><tr align="left"><td>Biology</td></tr><tr align="left"><td>Antinuclear antibodies</td></tr><tr align="left"><td>Anti-citrullinated cyclic peptides antibodies</td></tr><tr align="left"><td>Rheumatoid factor</td></tr><tr align="left"><td>Extractable Nuclear Antigens antibodies</td></tr><tr align="left"><td>&#160;</td></tr><tr align="left"><td><span class="elsevierStyleItalic">Occasional</span></td></tr><tr align="left"><td>Video-assisted surgical lung biopsy</td></tr><tr align="left"><td>Differential cell count of BAL</td></tr><tr align="left"><td>&#160;</td></tr><tr align="left"><td><span class="elsevierStyleItalic">Depending on context</span></td></tr><tr align="left"><td>Genetic testing</td></tr><tr align="left"><td>Anti-neutrophil cytoplasmic antibodies</td></tr><tr align="left"><td>Creatine phosphokinase</td></tr><tr align="left"><td>Anti-thyroid antibodies</td></tr><tr align="left"><td>Precipitins &#40;depending on disease presentation&#41;</td></tr><tr align="left"><td>Electrophoresis of serum proteins&#44; immuno-electrophoresis of serum proteins&#44; urine immunofixation and cryoglobulinaemia</td></tr><tr align="left"><td>Exploration for gastro-oesophageal reflux</td></tr><tr align="left"><td>Exploration for sleep apnoea syndrome</td></tr></table><p class="elsevierStylePara">Adapted from Cottin et al&#46;  <span class="elsevierStyleSup">3</span><br></br>6MWT&#58; 6-min walk test&#59; BAL&#58; bronchoalveolar lavage&#59; DLCO&#58; diffusing capacity of the lung for carbon monoxide&#59; HRCT&#58; high-resolution computed tomography&#46;<br></br></p><p class="elsevierStylePara">The general practice physician must be aware of IPF symptoms in order to consider this disease when establishing the initial diagnosis&#44; and to refer IPF suspicious cases to a pulmonologist&#46;</p><p class="elsevierStylePara">The diagnosis of IPF requires the exclusion of other known causes of interstitial lung disease &#40;domestic or occupational environmental exposures&#44; connective tissue disease&#44; drug toxicity&#41; and the presence of a typical histological UIP pattern&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib98" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">3</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib102" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">7</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib108" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">13</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib113" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">18</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib127" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">32</span></a> According to the ATS&#47;ERS recommendations and validated by international societies&#44; in the absence of biopsy&#44; IPF can be diagnosed only based on radiological criteria from the high resolution computed tomography &#40;HRCT&#41;&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a></p><p class="elsevierStylePara"><a href="&#35;f0005" class="elsevierStyleCrossRefs">Figure 1</a> presents the algorithm proposed for the diagnosis of IPF&#46; In case of IPF suspicion&#44; all the possible associations with UIP radiological pattern must be accurately investigated&#46; Since UIP pattern can be associated with several autoimmune diseases&#44; such as rheumatoid arthritis&#44; systemic sclerosis or Sj&#246;gren syndrome or even&#44; although rarely&#44; with ANCA-positive vasculitis&#44; all patients should perform serological autoimmune tests&#44; although positive anti-nuclear antibodies or rheumatoid factor can be detected in up to 20&#37; of IPF cases as an unspecific feature with no association with any particular disorder&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib127" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">32</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib128" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">33</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib129" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">34</span></a> The presence of serum specific IgG against the antigens that can frequently cause hypersensitivity pneumonitis should also be systematically assessed&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib125" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">30</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib129" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">34</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib130" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">35</span></a></p><a name="f0005" class="elsevierStyleCrossRefs"></a><p class="elsevierStylePara"><img src="320v22n02-90451464fig1.jpg" alt="IPF diagnosis algorithm&#46; ILD&#58; interstitial lung disease&#59; IPF&#58; idiopathic pulmonary fibrosis&#59; HRCT&#58; high-resolution computed tomography&#59; UIP&#58; usual interstitial pneumonia&#46;"></img></p><p class="elsevierStylePara">Figure 1&#46; IPF diagnosis algorithm&#46; ILD&#58; interstitial lung disease&#59; IPF&#58; idiopathic pulmonary fibrosis&#59; HRCT&#58; high-resolution computed tomography&#59; UIP&#58; usual interstitial pneumonia&#46;</p><p class="elsevierStylePara">Bronchoalveolar lavage &#40;BAL&#41; is not included in this algorithm as a diagnostic procedure since it is not recommended that BAL be systematically performed in all patients&#44; although it may be appropriate for a minority of cases&#46;<a href="&#35;bib98" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">3</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib131" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">36</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib132" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">37</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib133" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">38</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib134" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">39</span></a> Nevertheless&#44; Centres with experience in this approach might use BAL regularly as it can either rule out or help diagnose IPF&#44; especially when a higher lymphocytosis guides the diagnosis for other entities&#44; as for instance hypersensitivity pneumonitis&#46;<a href="&#35;bib132" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">37</span></a> On the other hand&#44; the use of transbronchial biopsy in the diagnosis of IPF is controversial&#46; Cryobiopsy&#44; although it is not yet widely used and must only be performed in Centres with experience in this procedure&#44; the published data so far shows that cryobiopsy in fibrotic ILDs yields large and well-preserved lung specimens&#44; sufficient to enclose all the UIP characteristic features&#44; with safety and tolerability&#46;<a href="&#35;bib135" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">40</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib136" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">41</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib137" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">42</span></a> In a recent cross-sectional study&#44; a comparison of cryobiopsies with surgical lung biopsies in fibrotic ILD by a multidisciplinary committee&#44; conclude a major increase in diagnostic confidence after the addition of cryobiopsies similar to surgical lung biopsy &#40;SLB&#41; in IPF diagnosis &#40;from 29&#37; to 63&#37;&#44; <span class="elsevierStyleItalic">p</span>&#160;&#61;&#160;0&#46;0003 and from 30&#37; to 65&#37;&#44; <span class="elsevierStyleItalic">p</span>&#160;&#61;&#160;0&#46;0016 of high confidence in the bronchoscopic lung cryobiopsy group and SLB group respectively&#41;&#44; which constitutes robust evidence of the potential role of this bronchologic procedure&#46;<a href="&#35;bib138" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">43</span></a></p><a name="sec0030" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">High resolution computed tomography</span><p class="elsevierStylePara">The purpose of HRCT is to identify the typical pattern of changes of UIP &#40;<a href="&#35;t0010" class="elsevierStyleCrossRefs">Table 2</a>&#41; or other patterns that may be present&#44; supporting the diagnosis of other lung diseases&#46; To standardize these radiological criteria&#44; the report should use descriptive concepts based on the terminology recommended by Fleischner Society&#46;<a href="&#35;bib139" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">44</span></a></p><p class="elsevierStylePara">Table 2&#46; High-resolution computed tomography&#39;s idiopathic pulmonary fibrosis&#47;usual interstitial pneumonia diagnosis criteria&#46;</p><a name="t0010" class="elsevierStyleCrossRefs"></a><p class="elsevierStylePara"></p><table><tr align="left"><td>UIP pattern &#40;all of the following&#41;</td><td>Possible UIP pattern &#40;all of the following&#41;</td><td>UIP-IPF pattern &#40;1&#160;&#43;&#160;2&#41;</td></tr><tr align="left"><td>1-Subpleural&#44; basal &#40;predominant distribution&#41;</td><td>1-Subpleural&#44; basal &#40;predominant distribution&#41;</td><td>1-All of UIP pattern</td></tr><tr align="left"><td>2-Reticulation</td><td>2-Reticulation</td><td>2-Absence of findings that do not support a UIP pattern</td></tr><tr align="left"><td>3-Honeycombing with or without traction bronchiectasis</td><td>3-Absence of findings that do not support a UIP pattern</td><td>&#160;</td></tr></table><p class="elsevierStylePara">Adapted from Raghu et al&#46;  <span class="elsevierStyleSup">1</span><br></br>IPF&#58; idiopathic pulmonary fibrosis&#59; UIP&#58; usual interstitial pneumonia&#46;<br></br></p><p class="elsevierStylePara">The identification of lung honeycombing is crucial for the diagnosis of IPF &#8211; they are cystic axial&#44; confluent or layered images&#44; with diameters of 3&#8211;10&#160;mm&#44; reaching 2&#46;5&#160;cm&#46; The distribution is usually subpleural or in the reticulation areas&#46;<a href="&#35;bib140" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">45</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib141" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">46</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib142" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">47</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib143" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">48</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib144" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">49</span></a></p><p class="elsevierStylePara">There are two aspects that may raise doubts in the HRTC interpretation&#58; the distinction between honeycombing and traction bronchiolectasis and fibrosis with emphysema&#46; The differential diagnosis is a challenge even for an experienced radiologist&#46;<a href="&#35;bib142" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">47</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib144" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">49</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib145" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">50</span></a> The 2011 ATS&#47;ERS&#47;JRS&#47;ALAT multidisciplinary consensus<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a> stated that the identification of four typical findings establishes the definite diagnosis of UIP&#58; 1 &#8211; subpleural and basal lung lesions predominance&#59; 2 &#8211; reticulation&#59; 3 &#8211; honeycombing with&#47;without traction bronchiectasis&#47;bronchiolectasis&#59; 4 &#8211; absence of findings that do not support a UIP pattern &#40;<a href="&#35;t0010" class="elsevierStyleCrossRefs">Table 2</a>&#44; <a href="&#35;t0015" class="elsevierStyleCrossRefs">Table 3</a>&#59; <a href="&#35;f0010" class="elsevierStyleCrossRefs">Figure 2</a>&#41;&#46;</p><p class="elsevierStylePara">Table 3&#46; Inconsistent criteria in the high-resolution computed tomography&#39;s idiopathic pulmonary fibrosis&#47;usual interstitial pneumonia diagnosis&#46;</p><a name="t0015" class="elsevierStyleCrossRefs"></a><p class="elsevierStylePara"></p><table><tr align="left"><td><span class="elsevierStyleBold">Any of the following</span></td></tr><tr align="left"><td><span class="elsevierStyleItalic">Predominance of middle or upper distribution</span></td></tr><tr align="left"><td><span class="elsevierStyleItalic">Peri-bronchovascular distribution</span></td></tr><tr align="left"><td><span class="elsevierStyleItalic">Reticular ground glass opacities</span></td></tr><tr align="left"><td><span class="elsevierStyleItalic">Micronodules &#40;bilateral and upper lobes predominance&#41;</span></td></tr><tr align="left"><td><span class="elsevierStyleItalic">Axial cysts &#40;multiple&#44; bilateral&#44; distant from the areas of honeycombing&#41;</span></td></tr><tr align="left"><td><span class="elsevierStyleItalic">Mosaic pattern&#44; diffuse&#47;air trapping &#40;bilateral&#44; in three or more lobes&#41;</span></td></tr><tr align="left"><td><span class="elsevierStyleItalic">Segment&#47;lobar consolidation</span></td></tr></table><p class="elsevierStylePara">Adapted from Raghu et al&#46;  <span class="elsevierStyleSup">1</span><br></br></p><a name="f0010" class="elsevierStyleCrossRefs"></a><p class="elsevierStylePara"><img src="320v22n02-90451464fig2a.jpg" alt="UIP&#47;IPF identification in HRCT and histopathology&#46; Case 1 &#8211; a&#58; Common histopathological features of UIP&#47;IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant&#46; HE 100&#215;&#46; Case 1 &#8211; b&#58; The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces&#46; HE 100&#215;&#46; Case 1 &#8211; c&#58; The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells&#44; either fibroblasts or miofibroblasts&#44; with collagen deposition&#46; Elastin-van Gieson 100&#215;&#46; Case 2 &#8211; a&#58; Irregular confluent air spaces with typical subpleural localization of UIP&#47;IPF honeycombing with interstitium enlargement by fusiform cells&#46; HE 100&#215;&#46; Case 2 &#8211; b&#58; The adjacent lobular parenchyma accentuate histopathological heterogeneity&#44; starting by overinflation and pseudo emphysema morphology&#46; HE 100&#215;&#46; Case 2 &#8211; c&#58; The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization&#46; HE 100&#215;&#46; Case 3 &#8211; a&#58; Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix&#59; lymphocytes are seen&#46; PAS 200&#215;&#46; Case 3 &#8211; b&#58; UIP&#47;IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule&#46; HE 100&#215;&#46;"></img></p><p class="elsevierStylePara">Figure 2&#46; UIP&#47;IPF identification in HRCT and histopathology&#46; Case 1 &#8211; a&#58; Common histopathological features of UIP&#47;IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant&#46; HE 100&#215;&#46; Case 1 &#8211; b&#58; The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces&#46; HE 100&#215;&#46; Case 1 &#8211; c&#58; The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells&#44; either fibroblasts or miofibroblasts&#44; with collagen deposition&#46; Elastin-van Gieson 100&#215;&#46; Case 2 &#8211; a&#58; Irregular confluent air spaces with typical subpleural localization of UIP&#47;IPF honeycombing with interstitium enlargement by fusiform cells&#46; HE 100&#215;&#46; Case 2 &#8211; b&#58; The adjacent lobular parenchyma accentuate histopathological heterogeneity&#44; starting by overinflation and pseudo emphysema morphology&#46; HE 100&#215;&#46; Case 2 &#8211; c&#58; The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization&#46; HE 100&#215;&#46; Case 3 &#8211; a&#58; Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix&#59; lymphocytes are seen&#46; PAS 200&#215;&#46; Case 3 &#8211; b&#58; UIP&#47;IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule&#46; HE 100&#215;&#46;</p><a name="f0010" class="elsevierStyleCrossRefs"></a><p class="elsevierStylePara"><img src="320v22n02-90451464fig2b.jpg" alt="UIP&#47;IPF identification in HRCT and histopathology&#46; Case 1 &#8211; a&#58; Common histopathological features of UIP&#47;IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant&#46; HE 100&#215;&#46; Case 1 &#8211; b&#58; The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces&#46; HE 100&#215;&#46; Case 1 &#8211; c&#58; The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells&#44; either fibroblasts or miofibroblasts&#44; with collagen deposition&#46; Elastin-van Gieson 100&#215;&#46; Case 2 &#8211; a&#58; Irregular confluent air spaces with typical subpleural localization of UIP&#47;IPF honeycombing with interstitium enlargement by fusiform cells&#46; HE 100&#215;&#46; Case 2 &#8211; b&#58; The adjacent lobular parenchyma accentuate histopathological heterogeneity&#44; starting by overinflation and pseudo emphysema morphology&#46; HE 100&#215;&#46; Case 2 &#8211; c&#58; The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization&#46; HE 100&#215;&#46; Case 3 &#8211; a&#58; Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix&#59; lymphocytes are seen&#46; PAS 200&#215;&#46; Case 3 &#8211; b&#58; UIP&#47;IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule&#46; HE 100&#215;&#46;"></img></p><p class="elsevierStylePara">Figure 2&#46; UIP&#47;IPF identification in HRCT and histopathology&#46; Case 1 &#8211; a&#58; Common histopathological features of UIP&#47;IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant&#46; HE 100&#215;&#46; Case 1 &#8211; b&#58; The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces&#46; HE 100&#215;&#46; Case 1 &#8211; c&#58; The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells&#44; either fibroblasts or miofibroblasts&#44; with collagen deposition&#46; Elastin-van Gieson 100&#215;&#46; Case 2 &#8211; a&#58; Irregular confluent air spaces with typical subpleural localization of UIP&#47;IPF honeycombing with interstitium enlargement by fusiform cells&#46; HE 100&#215;&#46; Case 2 &#8211; b&#58; The adjacent lobular parenchyma accentuate histopathological heterogeneity&#44; starting by overinflation and pseudo emphysema morphology&#46; HE 100&#215;&#46; Case 2 &#8211; c&#58; The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization&#46; HE 100&#215;&#46; Case 3 &#8211; a&#58; Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix&#59; lymphocytes are seen&#46; PAS 200&#215;&#46; Case 3 &#8211; b&#58; UIP&#47;IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule&#46; HE 100&#215;&#46;</p><a name="f0010" class="elsevierStyleCrossRefs"></a><p class="elsevierStylePara"><img src="320v22n02-90451464fig2c.jpg" alt="UIP&#47;IPF identification in HRCT and histopathology&#46; Case 1 &#8211; a&#58; Common histopathological features of UIP&#47;IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant&#46; HE 100&#215;&#46; Case 1 &#8211; b&#58; The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces&#46; HE 100&#215;&#46; Case 1 &#8211; c&#58; The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells&#44; either fibroblasts or miofibroblasts&#44; with collagen deposition&#46; Elastin-van Gieson 100&#215;&#46; Case 2 &#8211; a&#58; Irregular confluent air spaces with typical subpleural localization of UIP&#47;IPF honeycombing with interstitium enlargement by fusiform cells&#46; HE 100&#215;&#46; Case 2 &#8211; b&#58; The adjacent lobular parenchyma accentuate histopathological heterogeneity&#44; starting by overinflation and pseudo emphysema morphology&#46; HE 100&#215;&#46; Case 2 &#8211; c&#58; The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization&#46; HE 100&#215;&#46; Case 3 &#8211; a&#58; Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix&#59; lymphocytes are seen&#46; PAS 200&#215;&#46; Case 3 &#8211; b&#58; UIP&#47;IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule&#46; HE 100&#215;&#46;"></img></p><p class="elsevierStylePara">Figure 2&#46; UIP&#47;IPF identification in HRCT and histopathology&#46; Case 1 &#8211; a&#58; Common histopathological features of UIP&#47;IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant&#46; HE 100&#215;&#46; Case 1 &#8211; b&#58; The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces&#46; HE 100&#215;&#46; Case 1 &#8211; c&#58; The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells&#44; either fibroblasts or miofibroblasts&#44; with collagen deposition&#46; Elastin-van Gieson 100&#215;&#46; Case 2 &#8211; a&#58; Irregular confluent air spaces with typical subpleural localization of UIP&#47;IPF honeycombing with interstitium enlargement by fusiform cells&#46; HE 100&#215;&#46; Case 2 &#8211; b&#58; The adjacent lobular parenchyma accentuate histopathological heterogeneity&#44; starting by overinflation and pseudo emphysema morphology&#46; HE 100&#215;&#46; Case 2 &#8211; c&#58; The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization&#46; HE 100&#215;&#46; Case 3 &#8211; a&#58; Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix&#59; lymphocytes are seen&#46; PAS 200&#215;&#46; Case 3 &#8211; b&#58; UIP&#47;IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule&#46; HE 100&#215;&#46;</p><p class="elsevierStylePara">The HRCT positive predictive value in the diagnosis of UIP is 90&#8211;100&#37;&#46; The histopathology may also establish a UIP diagnosis in patients with no UIP lesions in the HRTC&#46;</p><p class="elsevierStylePara">The 2011 official ATS&#47;ERS&#47;JRS&#47;ALAT consensus established the use of &#8220;definitive&#8221; and &#8220;possible&#8221; IPF&#59; these definitions simplify the definitive diagnosis except for the other patients&#46; According with to this multidisciplinary consensus&#44; the diagnosis of UIP&#47;IPF must be based on the consensus between the clinician&#44; the radiologist and the pathologist&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a></p><a name="sec0035" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Histopathology</span><p class="elsevierStylePara">A surgical lung biopsy should establish the diagnosis of IPF if there are doubts about the presence of a definitive UIP typical pattern in the HRCT interpretation&#46; In patients with suspected IPF&#44; surgical lung biopsies should be obtained from multiple lobes&#44; avoiding the extremity of the lingula and middle lobe&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib146" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">51</span></a></p><p class="elsevierStylePara">The histological pattern of UIP must present&#58; 1 &#8211; marked fibrosis&#47;architectural distortion&#44; with or without honeycombing in a predominantly subpleural&#47;paraseptal distribution&#59; 2 &#8211; patchy involvement of lung parenchyma by fibrosis&#59; 3 &#8211; fibroblast foci&#59; 4 &#8211; absence of features against a diagnosis of UIP suggesting an alternate diagnosis<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib146" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">51</span></a> &#40;<a href="&#35;f0010" class="elsevierStyleCrossRefs">Figure 2</a>&#41;&#46;</p><p class="elsevierStylePara">In some diseases&#44; like rheumatoid arthritis&#44; chronic hypersensitivity pneumonitis or drug-induced pneumonitis&#44; asbestosis and familial fibrosis&#44; a histological pattern indistinguishable from UIP can be observed&#44; so the presence of granulomas&#44; asbestos bodies&#44; specific infections or other exogenous agents must be discarded in the biopsy&#46;<a href="&#35;bib108" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">13</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib146" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">51</span></a></p><p class="elsevierStylePara">The biopsy should only be performed after a multidisciplinary meeting where IPF diagnosis was not defined by HRCT&#59; if the biopsy is performed&#44; its results should again be discussed in a multidisciplinary meeting&#46;<a href="&#35;bib146" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">51</span></a></p><a name="sec0040" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Follow-up</span><p class="elsevierStylePara">It is recommended that IPF patients perform a follow-up clinic visit every 3&#8211;6 months&#46; <a href="&#35;t0020" class="elsevierStyleCrossRefs">Table 4</a> presents the main examinations that are useful for IPF management&#46;</p><p class="elsevierStylePara">Table 4&#46; Idiopathic pulmonary fibrosis management examinations&#46;</p><a name="t0020" class="elsevierStyleCrossRefs"></a><p class="elsevierStylePara"></p><table><tr align="left"><td><span class="elsevierStyleBold">During IPF follow-up</span></td></tr><tr align="left"><td><span class="elsevierStyleItalic">Every 6 months</span></td></tr><tr align="left"><td>FVC and DLCO</td></tr><tr align="left"><td>Arterial blood gas in room air</td></tr><tr align="left"><td>6MWT</td></tr><tr align="left"><td>Chest X ray</td></tr><tr align="left"><td>&#160;</td></tr><tr align="left"><td><span class="elsevierStyleItalic">Depending on context</span></td></tr><tr align="left"><td>Chest HRCT</td></tr><tr align="left"><td>Doppler echocardiography</td></tr><tr align="left"><td>TLC</td></tr><tr align="left"><td>Right heart catheterization</td></tr></table><p class="elsevierStylePara">Adapted from Cottin et al&#46;  <span class="elsevierStyleSup">3</span><br></br>6MWT&#58; 6-min walk test&#59; DLCO&#58; diffusing capacity of the lung for carbon monoxide&#59; FVC&#58; forced vital capacity&#59; HRCT&#58; high-resolution computed tomography&#59; TLC&#58; total lung capacity&#46;<br></br></p><a name="sec0045" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Patient flow</span><p class="elsevierStylePara">Setting an IPF patient flow&#44; which defines the several steps from diagnosis to treatment&#44; may represent the identification of more cases of IPF&#44; in a shorter period of time and in early stages of the disease &#40;<a href="&#35;f0015" class="elsevierStyleCrossRefs">Figure 3</a>&#41;&#46;</p><a name="f0015" class="elsevierStyleCrossRefs"></a><p class="elsevierStylePara"><img src="320v22n02-90451464fig3.jpg" alt="Idiopathic pulmonary fibrosis patient flow&#46; HRCT&#58; high-resolution computed tomography&#46;"></img></p><p class="elsevierStylePara">Figure 3&#46; Idiopathic pulmonary fibrosis patient flow&#46; HRCT&#58; high-resolution computed tomography&#46;</p><a name="sec0050" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Pharmacological treatment</span><p class="elsevierStylePara">The therapeutic strategy in IPF should be individualized for each patient&#44; considering the evaluation of potential benefits and risks&#46; It is more important to take into account the clinical behaviour than the respiratory function parameters&#46;<a href="&#35;bib147" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">52</span></a></p><p class="elsevierStylePara">Nintedanib and pirfenidone&#44; two compounds with pleiotropic mechanisms of action are&#44; to date&#44; the two drugs with confirmed efficacy in slowing functional decline and disease progression in IPF patients&#46;<a href="&#35;bib102" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">7</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib148" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">53</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib149" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">54</span></a></p><a name="sec0055" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Nintedanib</span><p class="elsevierStylePara">Nintedanib is a tyrosine kinase inhibitor small molecule that targets receptors of growth factors&#44; specifically inhibits platelet-derived growth factor receptor &#40;PDGFR&#41;&#44; fibroblasts growth factor receptor &#40;FGFR&#41; and vascular endothelial growth factor receptor &#40;VEGFR&#41;&#44;<a href="&#35;bib150" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">55</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib151" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">56</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib152" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">57</span></a> involved in the lung fibrosis mechanism&#46; It is believed that nintedanib reduces the progression of the disease and the decline in lung function by blocking the signalling pathways involved in the fibrotic processes&#46;<a href="&#35;bib150" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">55</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib151" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">56</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib152" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">57</span></a></p><p class="elsevierStylePara">The TOMORROW Phase II trial showed that nintedanib&#44; 150&#160;mg twice daily&#44; was effective in reducing forced vital capacity &#40;FVC&#41; decline&#44; in preventing acute exacerbations&#44; and preserving health-related quality of life &#40;HRQoL&#41;&#46;<a href="&#35;bib104" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">9</span></a> The phase III INPULSIS-1 and INPULSIS-2 trials&#44; showed that nintedanib slowed disease progression&#44; reducing the annual rate of lung function decline of 50&#37;&#46;<a href="&#35;bib106" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">11</span></a> It also presented a 68&#37; reduction of adjudicated acute exacerbations&#44;<a href="&#35;bib106" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">11</span></a> which can be crucial since approximately 50&#37; of IPF acute exacerbation admitted patients die during hospitalization&#46;<a href="&#35;bib153" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">58</span></a> After the first publication further subgroup analysis of pooled data from the INPULSIS trials demonstrated that nintedanib slowed disease progression by reducing the annual rate of FVC decline independently of the FVC value &#40;FVC &#62;80&#37; versus &#60;80&#37; or FVC &#62;70&#37; versus &#60;70&#37;&#41;&#44; of the presence of emphysema at baseline&#44; of the presence of honeycombing and&#47;or biopsy confirmation of UIP or in the absence of both&#44; namely the presence of &#8220;possible UIP&#8221; on HRCT scan without histology confirmation&#46;</p><p class="elsevierStylePara">Although these studies were not dimensioned to detect statistical differences in mortality&#44; the pooled analysis of data from the TOMORROW and INPULSIS trials shows a trend towards reduction in mortality&#44; since after 52 weeks the proportion of patients who died from any cause was 5&#46;8&#37; in the nintendanib arm and 8&#46;3&#37; in the placebo group &#40;HR 0&#46;70 &#91;95&#37; CI&#58; 0&#46;46&#44; 1&#46;08&#93;&#59; <span class="elsevierStyleItalic">p</span>&#160;&#61;&#160;0&#46;0955&#41;&#46; Respiratory mortality was also comparatively low in the nintendanib arm &#40;3&#46;6&#37; versus 5&#46;7&#37; &#8211; HR 0&#46;62 &#91;95&#37; CI&#58; 0&#46;37&#44; 1&#46;06&#93;&#59; <span class="elsevierStyleItalic">p</span>&#160;&#61;&#160;0&#46;0779&#41;&#46;<a href="&#35;bib106" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">11</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib154" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">59</span></a></p><p class="elsevierStylePara">The most frequent adverse events during these trials were diarrhoea&#44; nausea and vomiting&#44; that can be easily managed in most patients&#46;<a href="&#35;bib106" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">11</span></a></p><p class="elsevierStylePara">Nintedanib is approved in the US and EU for the treatment of IPF patients&#44; regardless of disease severity&#44; under the brand name OFEV<span class="elsevierStyleSup">&#174;</span>&#46;</p><a name="sec0060" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Pirfenidone</span><p class="elsevierStylePara">Pirfenidone is a pyridine compound with antifibrotic and anti-inflammatory properties&#44; indicated for the treatment of mild to moderate IPF&#46;<a href="&#35;bib155" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">60</span></a> The mechanism of action of pirfenidone has not been fully established&#44; but it is known that pirfenidone attenuates fibroblast proliferation&#44; production of fibrosis-associated proteins and cytokines&#44; and the increased biosynthesis and accumulation of extracellular matrix in response to cytokine growth factors such as transforming growth factor-beta &#40;TGF-&#946;&#41; and platelet-derived growth factor &#40;PDGF&#41;&#46;<a href="&#35;bib155" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">60</span></a></p><p class="elsevierStylePara">Despite the conflicting outcomes related to FVC decline in the CAPACITY trials 004 and 006&#44; the pooled data <a href="&#35;bib103" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">8</span></a> showed a pirfenidone treatment effect in percentage predicted FVC at week 72 with a dose of 2403&#160;mg&#47;day &#40;&#8722;8&#46;5&#37; versus &#8722;11&#46;0&#37;&#59; <span class="elsevierStyleItalic">p</span>&#160;&#61;&#160;0&#46;005&#41; and a smaller proportion of patients with a FVC decline &#8805;10&#37;&#46; Pirfenidone also prolonged progression free survival by 23&#37; when compared with placebo&#46;<a href="&#35;bib103" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">8</span></a> A 31&#37; relative difference favouring pirfenidone<a href="&#35;bib103" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">8</span></a> was noted related to 6-min walk test &#40;6MWT&#41; also at week 72&#46; The posterior phase III ASCEND trial showed a reduction of 47&#46;9&#37; of patients with a FVC percentage predicted value decline &#8805;10&#37; or who died&#46;<a href="&#35;bib105" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">10</span></a> There was also an increase of 132&#46;5&#37; in proportion of patients with no decline in FVC &#40;<span class="elsevierStyleItalic">p</span>&#160;&#60;&#160;0&#46;001&#41;&#46;<a href="&#35;bib105" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">10</span></a> A reduced decline in 6MWT &#40;<span class="elsevierStyleItalic">p</span>&#160;&#61;&#160;0&#46;04&#41; and an improved progression free survival &#40;<span class="elsevierStyleItalic">p</span>&#160;&#60;&#160;0&#46;001&#41; were also noted&#46;<a href="&#35;bib105" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">10</span></a></p><p class="elsevierStylePara">Moreover&#44; in a pooled analysis enclosing CAPACITY and ASCEND trials&#44; there was a significant difference in death cases from any causes between patients treated with pirfenidone and placebo &#40;<span class="elsevierStyleItalic">p</span>&#160;&#61;&#160;0&#46;01&#41; and death related with IPF &#40;<span class="elsevierStyleItalic">p</span>&#160;&#61;&#160;0&#46;006&#41;&#46;<a href="&#35;bib105" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">10</span></a></p><p class="elsevierStylePara">In a recent pooled data analysis of outcomes at 1 year in CAPACITY and ASCEND trials including a total of 1247 patients pirfenidone reduced the proportion of patients with a &#8805;10&#37; decline in FVC percentage or death by 43&#46;8&#37; &#40;95&#37; CI 29&#46;3&#8211;55&#46;4&#37;&#41; and increased the proportion of patients with no decline by 59&#46;3&#37; &#40;95&#37; CI 29&#46;0&#8211;96&#46;8&#37;&#41;&#46; Progression free survival&#44; 6MWT and dyspnoea also showed a positive impact from pirfenidone&#46; These results provided further evidence about the benefit of pirfenidone in IPF disease progression&#46;<a href="&#35;bib156" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">61</span></a></p><p class="elsevierStylePara">The most common adverse events during these trials were photosensibility&#44; gastro-intestinal occurrences and gastro-oesophageal reflux&#44; generally reversible with dose reductions&#46;<a href="&#35;bib103" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">8</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib105" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">10</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib157" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">62</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib158" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">63</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib159" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">64</span></a></p><p class="elsevierStylePara">Pirfenidone is approved for the treatment of mild to moderate IPF patients&#44; under the brand name of Esbriet<span class="elsevierStyleSup">&#174;</span>&#46;</p><p class="elsevierStylePara">Although some data is available related with the concomitant therapy with nintedanib and pirfenidone&#44; this approach cannot be recommended since its efficacy and tolerability is not sufficiently evidenced&#46;<a href="&#35;bib160" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">65</span></a></p><a name="sec0065" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Other drugs</span><p class="elsevierStylePara">After the IFIGENIA study&#44;<a href="&#35;bib161" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">66</span></a> N-acetylcysteine &#40;NAC&#41; combined with prednisone and azathioprine was the treatment of choice for several years&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a> With the presentation of the subsequent PANTHER study&#44;<a href="&#35;bib162" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">67</span></a> which showed higher mortality and hospital admissions in patients receiving NAC combination therapy compared to placebo or NAC alone&#44; the triple therapy is not recommended&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a> Additionally&#44; NAC as monotherapy did not show efficacy versus placebo&#46;<a href="&#35;bib163" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">68</span></a></p><p class="elsevierStylePara">Various compounds&#44; including anti-coagulants&#44; interferon gamma-1b&#44; anti-acids&#44; anti-inflammatory and vasodilator agents<a href="&#35;bib120" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">25</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib135" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">40</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib164" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">69</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib165" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">70</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib166" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">71</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib167" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">72</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib168" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">73</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib169" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">74</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib170" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">75</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib171" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">76</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib172" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">77</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib173" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">78</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib174" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">79</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib175" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">80</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib176" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">81</span></a> have been tested in IPF patients but have not demonstrated definitive efficacy for the treatment of IPF&#46; In addition&#44; there are currently several ongoing clinical trials results of which will be available in the near future&#46;</p><a name="sec0070" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Non-pharmacological treatment</span><a name="sec0075" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Respiratory rehabilitation</span><p class="elsevierStylePara">Pulmonary rehabilitation in IPF has showed an improvement in walking distance&#44; symptoms and HRQoL&#46; Although the long term benefit of rehabilitation is not demonstrated&#44; it is recommended for the majority of patients&#44; namely in early stages of the disease&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib177" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">82</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib178" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">83</span></a></p><a name="sec0080" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Oxygen therapy</span><p class="elsevierStylePara">Although there are no specific data concerning the use of long-term oxygen therapy in patients with IPF&#44; based on chronic obstructive pulmonary disease &#40;COPD&#41; and chronic respiratory failures studies&#44; it is recommended to all IPF patients with resting hypoxaemia&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a></p><a name="sec0085" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Lung transplant</span><p class="elsevierStylePara">In cases that meet the criteria&#44; lung transplant must be always kept in mind since it is&#44; according to the international recommendations&#44; the most effective and reliable treatment for patients with IPF&#46; Lung transplantation 5-years survival rate ranges from 50&#37; to 56&#37; and 10-years survival rate is 30&#37;&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib179" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">84</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib180" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">85</span></a></p><a name="sec0090" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Treatment of complications and comorbidities</span><a name="sec0095" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Acute exacerbation</span><p class="elsevierStylePara">High-dose corticosteroid therapy with or without immunosuppressive agents&#44; namely cyclophosphamide&#44; and wide spectrum antibiotics&#44; are the most widely used treatments for the acute exacerbation of IPF despite the lack of conclusive evidence demonstrating their benefits&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib181" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">86</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib182" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">87</span></a></p><a name="sec0100" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Gastro-oesophageal reflux</span><p class="elsevierStylePara">Asymptomatic GER is common in IPF and may impact IPF natural history and progression&#46;<a href="&#35;bib183" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">88</span></a> An analysis of data from three randomized controlled trials showed that IPF patients taking proton pump inhibitors &#40;PPI&#41; and&#47;or H2 inhibitors significantly slower decline in FVC over time&#46;<a href="&#35;bib120" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">25</span></a> According to the international recommendations&#44; asymptomatic GER should be treated in the majority of patients with IPF&#44; namely with PPI&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib148" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">53</span></a></p><a name="sec0105" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Pulmonary hypertension</span><p class="elsevierStylePara">In two uncontrolled prospective studies of sildenafil in patients with pulmonary hypertension in context of IPF&#44; walk distance and pulmonary haemodynamics improved after 8&#8211;12 weeks of treatment&#46;<a href="&#35;bib184" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">89</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib185" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">90</span></a> In the randomized controlled STEP-IPF &#40;Sildenafil Trial of Exercise Performance in IPF&#41; trial&#44; comparing 20&#160;mg tid of sildenafil and placebo over 12 weeks&#44; no significant improvement of the 6MWT &#40;primary end-point&#41; was observed&#59; however arterial oxygenation&#44; diffusing capacity of the lung for carbon monoxide &#40;DLCO&#41;&#44; dyspnoea and quality of life were improved in patients on sildenafil&#46;<a href="&#35;bib175" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">80</span></a></p><p class="elsevierStylePara">However&#44; in a subgroup analysis of patients with right ventricular systolic dysfunction echocardiogram-documented&#44; sildenafil treatment resulted in a significant improvement in the primary outcome of 6MWT &#40;mean distance&#44; 99&#46;3&#160;m&#59; 95&#37; CI 22&#46;3&#8211;176&#46;2&#160;m&#41;&#46;<a href="&#35;bib186" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">91</span></a> Considering these results&#44; although without a clear recommendation&#44; sildenafil can be one option in patients with IPF and pulmonary hypertension with right ventricular dysfunction&#46;</p><p class="elsevierStylePara">Due to lack of evidence&#44; any drug from prostacycline analogues or endothelin receptor antagonists &#40;ERA&#41; are not indicated for use in IPF&#46;<a href="&#35;bib147" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">52</span></a> Moreover&#44; ambrisentan&#44; an ERA&#44; is contraindicated in IPF&#44; since the ARTEMIS-IPF randomized controlled trial showed an increase number of hospitalizations for respiratory complications&#46;<a href="&#35;bib187" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">92</span></a></p><a name="sec0110" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Palliative care</span><p class="elsevierStylePara">The aim of palliative care is to improve patients&#8217; quality of life&#46; It is important to take into account not only the symptoms related with the disease progression&#44; like cough and dyspnoea&#44; where codeine and morphine have shown to be effective&#44; but also psychological aspects inherent to those who face this poor prognostic and great disabling disease&#46;<a href="&#35;bib96" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib188" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">93</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib189" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">94</span></a><span class="elsevierStyleSup">&#44; </span><a href="&#35;bib190" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">95</span></a></p><a name="sec0115" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Conclusions</span><p class="elsevierStylePara">To change the scenario of this devastating disease&#44; early identification and referral of IPF patients to a specialized centre is needed&#46; Training of General Practitioners and further awareness of pulmonologists not specialized in IPF is essential to achieve this&#46;</p><p class="elsevierStylePara">Every patient older than 50 years of age&#44; with exertional dyspnoea and dry&#44; non-productive cough&#44; with ongoing or previous smoking habits and bi-basal crackles on auscultation&#44; should have rapid access to a multidisciplinary team&#46;</p><p class="elsevierStylePara">This multidisciplinary approach demands the judicious use&#44; not only of HRCT information and histopathology when needed&#44; but also of all non-standardized data available in individual patients&#44; such as BAL&#44; serology tests and biomarkers&#46;</p><p class="elsevierStylePara">Unfortunately specific biomarkers are yet to be found and less invasive methods to reach lung tissue are far from being established&#46;</p><p class="elsevierStylePara">Nevertheless recent advances in clinical research allowed the release of new and promising molecules&#44; nintedanib and pirfenidone&#44; two antifibrotic drugs with diverse mechanisms of action that presented efficacy in slowing functional decline and disease progression in IPF patients&#46;</p><p class="elsevierStylePara">Finally it must be stressed that in IPF the therapeutic strategy should be individualized to each patient&#44; considering&#44; not only the evaluation of potential benefits and risks&#44; but also and most importantly&#44; taking into account the clinical behaviour of the disease&#46;</p><p class="elsevierStylePara">Corresponding author&#46; carlos&#46;crobalo&#64;gmail&#46;com</p>"
    "pdfFichero" => "320v22n02a90451464pdf001.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:1 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec640949"
          "palabras" => array:4 [
            0 => "Idiopathic pulmonary fibrosis"
            1 => "Guideline"
            2 => "Diagnosis"
            3 => "Therapeutics"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:1 [
      "en" => array:1 [
        "resumen" => "<p class="elsevierStylePara">Idiopathic pulmonary fibrosis is a rare interstitial lung disease included in the Idiopathic Interstitial Pneumonias group&#46; Although several potential risk factors have been described&#44; it is a progressive fibrosing disease of unknown cause affecting mainly adults over 50 years and associated with a poor prognosis&#44; reflected in a median survival of 2&#8211;3 years after diagnosis&#46;</p><p class="elsevierStylePara">The concept of a multidisciplinary working group for the diagnosis of idiopathic pulmonary fibrosis is based on the need to have experienced pulmonologists&#44; radiologists and pathologists in the evaluation and correct treatment of the disease&#44; and requires the use of all available data about individual patients&#44; standardized &#40;largely through High Resolution Computed Tomography and pathology when needed&#41; as well as non-standardized data &#40;laboratory&#44; serology and biomarkers&#41;&#46; This approach helps to increase diagnostic accuracy and is an internationally accepted recommendation&#46;</p><p class="elsevierStylePara">In regard to therapy&#44; the situation has changed radically since the publication of the ATS&#47;ERS&#47;JRS&#47;ALAT 2011 guidelines on the diagnosis and management of idiopathic pulmonary fibrosis where it was stressed that no proven therapy exists for this disease&#46;</p><p class="elsevierStylePara">Currently besides non-pharmacological treatment&#44; therapy of complications and comorbidities and palliative care&#44; nintedanib and pirfenidone&#44; two compounds with pleiotropic mechanisms of action&#44; are to date&#44; the two drugs with confirmed efficacy in slowing functional decline and disease progression in idiopathic pulmonary fibrosis patients&#46;</p>"
      ]
    ]
    "multimedia" => array:10 [
      0 => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "320v22n02-90451464fig1.jpg"
            "Alto" => 2688
            "Ancho" => 2167
            "Tamanyo" => 410222
          ]
        ]
        "descripcion" => array:1 [
          "en" => "IPF diagnosis algorithm&#46; ILD&#58; interstitial lung disease&#59; IPF&#58; idiopathic pulmonary fibrosis&#59; HRCT&#58; high-resolution computed tomography&#59; UIP&#58; usual interstitial pneumonia&#46;"
        ]
      ]
      1 => array:8 [
        "identificador" => "fig2"
        "etiqueta" => "Figure 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "320v22n02-90451464fig2a.jpg"
            "Alto" => 1360
            "Ancho" => 1800
            "Tamanyo" => 1230542
          ]
        ]
        "descripcion" => array:1 [
          "en" => "UIP&#47;IPF identification in HRCT and histopathology&#46; Case 1 &#191; a&#58; Common histopathological features of UIP&#47;IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant&#46; HE 100&#215;&#46; Case 1 &#191; b&#58; The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces&#46; HE 100&#215;&#46; Case 1 &#191; c&#58; The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells&#44; either fibroblasts or miofibroblasts&#44; with collagen deposition&#46; Elastin-van Gieson 100&#215;&#46; Case 2 &#191; a&#58; Irregular confluent air spaces with typical subpleural localization of UIP&#47;IPF honeycombing with interstitium enlargement by fusiform cells&#46; HE 100&#215;&#46; Case 2 &#191; b&#58; The adjacent lobular parenchyma accentuate histopathological heterogeneity&#44; starting by overinflation and pseudo emphysema morphology&#46; HE 100&#215;&#46; Case 2 &#191; c&#58; The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization&#46; HE 100&#215;&#46; Case 3 &#191; a&#58; Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix&#59; lymphocytes are seen&#46; PAS 200&#215;&#46; Case 3 &#191; b&#58; UIP&#47;IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule&#46; HE 100&#215;&#46;"
        ]
      ]
      2 => array:8 [
        "identificador" => "fig3"
        "etiqueta" => "Figure 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "320v22n02-90451464fig2b.jpg"
            "Alto" => 1361
            "Ancho" => 1800
            "Tamanyo" => 1118548
          ]
        ]
        "descripcion" => array:1 [
          "en" => "UIP&#47;IPF identification in HRCT and histopathology&#46; Case 1 &#191; a&#58; Common histopathological features of UIP&#47;IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant&#46; HE 100&#215;&#46; Case 1 &#191; b&#58; The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces&#46; HE 100&#215;&#46; Case 1 &#191; c&#58; The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells&#44; either fibroblasts or miofibroblasts&#44; with collagen deposition&#46; Elastin-van Gieson 100&#215;&#46; Case 2 &#191; a&#58; Irregular confluent air spaces with typical subpleural localization of UIP&#47;IPF honeycombing with interstitium enlargement by fusiform cells&#46; HE 100&#215;&#46; Case 2 &#191; b&#58; The adjacent lobular parenchyma accentuate histopathological heterogeneity&#44; starting by overinflation and pseudo emphysema morphology&#46; HE 100&#215;&#46; Case 2 &#191; c&#58; The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization&#46; HE 100&#215;&#46; Case 3 &#191; a&#58; Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix&#59; lymphocytes are seen&#46; PAS 200&#215;&#46; Case 3 &#191; b&#58; UIP&#47;IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule&#46; HE 100&#215;&#46;"
        ]
      ]
      3 => array:8 [
        "identificador" => "fig4"
        "etiqueta" => "Figure 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "320v22n02-90451464fig2c.jpg"
            "Alto" => 664
            "Ancho" => 1800
            "Tamanyo" => 650314
          ]
        ]
        "descripcion" => array:1 [
          "en" => "UIP&#47;IPF identification in HRCT and histopathology&#46; Case 1 &#191; a&#58; Common histopathological features of UIP&#47;IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant&#46; HE 100&#215;&#46; Case 1 &#191; b&#58; The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces&#46; HE 100&#215;&#46; Case 1 &#191; c&#58; The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells&#44; either fibroblasts or miofibroblasts&#44; with collagen deposition&#46; Elastin-van Gieson 100&#215;&#46; Case 2 &#191; a&#58; Irregular confluent air spaces with typical subpleural localization of UIP&#47;IPF honeycombing with interstitium enlargement by fusiform cells&#46; HE 100&#215;&#46; Case 2 &#191; b&#58; The adjacent lobular parenchyma accentuate histopathological heterogeneity&#44; starting by overinflation and pseudo emphysema morphology&#46; HE 100&#215;&#46; Case 2 &#191; c&#58; The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization&#46; HE 100&#215;&#46; Case 3 &#191; a&#58; Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix&#59; lymphocytes are seen&#46; PAS 200&#215;&#46; Case 3 &#191; b&#58; UIP&#47;IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule&#46; HE 100&#215;&#46;"
        ]
      ]
      4 => array:8 [
        "identificador" => "fig5"
        "etiqueta" => "Figure 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "320v22n02-90451464fig3.jpg"
            "Alto" => 3103
            "Ancho" => 1000
            "Tamanyo" => 398528
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Idiopathic pulmonary fibrosis patient flow&#46; HRCT&#58; high-resolution computed tomography&#46;"
        ]
      ]
      5 => array:6 [
        "identificador" => "fig6"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "descripcion" => array:1 [
          "en" => "IPF diagnosis algorithm&#46; ILD&#58; interstitial lung disease&#59; IPF&#58; idiopathic pulmonary fibrosis&#59; HRCT&#58; high-resolution computed tomography&#59; UIP&#58; usual interstitial pneumonia&#46;"
        ]
      ]
      6 => array:6 [
        "identificador" => "fig7"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "descripcion" => array:1 [
          "en" => "UIP&#47;IPF identification in HRCT and histopathology&#46; Case 1 &#8211; a&#58; Common histopathological features of UIP&#47;IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant&#46; HE 100&#215;&#46; Case 1 &#8211; b&#58; The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces&#46; HE 100&#215;&#46; Case 1 &#8211; c&#58; The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells&#44; either fibroblasts or miofibroblasts&#44; with collagen deposition&#46; Elastin-van Gieson 100&#215;&#46; Case 2 &#8211; a&#58; Irregular confluent air spaces with typical subpleural localization of UIP&#47;IPF honeycombing with interstitium enlargement by fusiform cells&#46; HE 100&#215;&#46; Case 2 &#8211; b&#58; The adjacent lobular parenchyma accentuate histopathological heterogeneity&#44; starting by overinflation and pseudo emphysema morphology&#46; HE 100&#215;&#46; Case 2 &#8211; c&#58; The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization&#46; HE 100&#215;&#46; Case 3 &#8211; a&#58; Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix&#59; lymphocytes are seen&#46; PAS 200&#215;&#46; Case 3 &#8211; b&#58; UIP&#47;IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule&#46; HE 100&#215;&#46;"
        ]
      ]
      7 => array:6 [
        "identificador" => "fig8"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "descripcion" => array:1 [
          "en" => "UIP&#47;IPF identification in HRCT and histopathology&#46; Case 1 &#8211; a&#58; Common histopathological features of UIP&#47;IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant&#46; HE 100&#215;&#46; Case 1 &#8211; b&#58; The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces&#46; HE 100&#215;&#46; Case 1 &#8211; c&#58; The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells&#44; either fibroblasts or miofibroblasts&#44; with collagen deposition&#46; Elastin-van Gieson 100&#215;&#46; Case 2 &#8211; a&#58; Irregular confluent air spaces with typical subpleural localization of UIP&#47;IPF honeycombing with interstitium enlargement by fusiform cells&#46; HE 100&#215;&#46; Case 2 &#8211; b&#58; The adjacent lobular parenchyma accentuate histopathological heterogeneity&#44; starting by overinflation and pseudo emphysema morphology&#46; HE 100&#215;&#46; Case 2 &#8211; c&#58; The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization&#46; HE 100&#215;&#46; Case 3 &#8211; a&#58; Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix&#59; lymphocytes are seen&#46; PAS 200&#215;&#46; Case 3 &#8211; b&#58; UIP&#47;IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule&#46; HE 100&#215;&#46;"
        ]
      ]
      8 => array:6 [
        "identificador" => "fig9"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "descripcion" => array:1 [
          "en" => "UIP&#47;IPF identification in HRCT and histopathology&#46; Case 1 &#8211; a&#58; Common histopathological features of UIP&#47;IPF consisting in honeycombing as a result of subpleural airway spaces confluence with bronchialization of epithelium where mucus cells may be predominant&#46; HE 100&#215;&#46; Case 1 &#8211; b&#58; The previous image aspects are revealed by higher production of mucus occupying the new formed subpleural smaller confluent airspaces&#46; HE 100&#215;&#46; Case 1 &#8211; c&#58; The interstitium intermingling honey-combing loses elastin fibres and is represented by fusiform cells&#44; either fibroblasts or miofibroblasts&#44; with collagen deposition&#46; Elastin-van Gieson 100&#215;&#46; Case 2 &#8211; a&#58; Irregular confluent air spaces with typical subpleural localization of UIP&#47;IPF honeycombing with interstitium enlargement by fusiform cells&#46; HE 100&#215;&#46; Case 2 &#8211; b&#58; The adjacent lobular parenchyma accentuate histopathological heterogeneity&#44; starting by overinflation and pseudo emphysema morphology&#46; HE 100&#215;&#46; Case 2 &#8211; c&#58; The lobular histopathological remodelling aspect of fibrosis enlarging alveoli septae till central bronchiolo-vascular axes and alveolar bronchialization&#46; HE 100&#215;&#46; Case 3 &#8211; a&#58; Small subpeural confluent air-spaces with bronchial-like epithelium and juvenile foci of fibroblasts in myxoid matrix&#59; lymphocytes are seen&#46; PAS 200&#215;&#46; Case 3 &#8211; b&#58; UIP&#47;IPF heterogeneous morphology in airspaces confluence with subpleural preponderance and committing the whole lobule&#46; HE 100&#215;&#46;"
        ]
      ]
      9 => array:6 [
        "identificador" => "fig10"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "descripcion" => array:1 [
          "en" => "Idiopathic pulmonary fibrosis patient flow&#46; HRCT&#58; high-resolution computed tomography&#46;"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliography"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:95 [
            0 => array:3 [
              "identificador" => "bib96"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence&#x002D;based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183:788&#x002D;824."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "An official ATS&#47;ERS&#47;JRS&#47;ALAT statement&#58; idiopathic pulmonary fibrosis&#58; evidence-based guidelines for diagnosis and management&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/rccm.2009-040GL"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med. "
                        "fecha" => "2011"
                        "volumen" => "183"
                        "paginaInicial" => "788"
                        "paginaFinal" => "824"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib97"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Idiopathic pulmonary fibrosis. Lancet. 2011; 378:1949&#x002D;61."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(11)60052-4"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet. "
                        "fecha" => "2011"
                        "volumen" => "378"
                        "paginaInicial" => "1949"
                        "paginaFinal" => "1961"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib98"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines. Eur Respir Rev. 2014; 23:193&#x002D;214."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Diagnosis and management of idiopathic pulmonary fibrosis&#58; French practical guidelines&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1183/09059180.00001814"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Respir Rev. "
                        "fecha" => "2014"
                        "volumen" => "23"
                        "paginaInicial" => "193"
                        "paginaFinal" => "214"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib99"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Idiopathic pulmonary fibrosis: evolving concepts. Mayo Clin Proc. 2014; 89:1130&#x002D;42."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Idiopathic pulmonary fibrosis&#58; evolving concepts&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.mayocp.2014.03.016"
                      "Revista" => array:6 [
                        "tituloSerie" => "Mayo Clin Proc. "
                        "fecha" => "2014"
                        "volumen" => "89"
                        "paginaInicial" => "1130"
                        "paginaFinal" => "1142"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib100"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Why do patients get idiopathic pulmonary fibrosis? Current concepts in the pathogenesis of pulmonary fibrosis. BMC Med. 2015; 13:176."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Why do patients get idiopathic pulmonary fibrosis&#63; Current concepts in the pathogenesis of pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/s12916-015-0412-6"
                      "Revista" => array:5 [
                        "tituloSerie" => "BMC Med. "
                        "fecha" => "2015"
                        "volumen" => "13"
                        "paginaInicial" => "176"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib101"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000; 161:646&#x002D;64."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Idiopathic pulmonary fibrosis&#58; diagnosis and treatment&#46; International consensus statement&#46; American Thoracic Society &#40;ATS&#41;&#44; and the European Respiratory Society &#40;ERS&#41;&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/ajrccm.161.2.ats3-00"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med. "
                        "fecha" => "2000"
                        "volumen" => "161"
                        "paginaInicial" => "646"
                        "paginaFinal" => "664"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib102"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy. Pharmacol Ther. 2015. pii:S0163&#x002D;7258(15)00091&#x002D;1"
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Idiopathic pulmonary fibrosis&#58; recent advances on pharmacological therapy&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.pharmthera.2007.04.009"
                      "Revista" => array:3 [
                        "tituloSerie" => "Pharmacol Ther. "
                        "fecha" => "2015"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib103"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377:1760&#x002D;9."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Pirfenidone in patients with idiopathic pulmonary fibrosis &#40;CAPACITY&#41;&#58; two randomised trials&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(11)60405-4"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet. "
                        "fecha" => "2011"
                        "volumen" => "377"
                        "paginaInicial" => "1760"
                        "paginaFinal" => "1769"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib104"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011; 365:1079&#x002D;87."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1103690"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med. "
                        "fecha" => "2011"
                        "volumen" => "365"
                        "paginaInicial" => "1079"
                        "paginaFinal" => "1087"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib105"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370:2083&#x002D;92."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1402582"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med. "
                        "fecha" => "2014"
                        "volumen" => "370"
                        "paginaInicial" => "2083"
                        "paginaFinal" => "2092"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib106"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370:2071&#x002D;82."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1402584"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med. "
                        "fecha" => "2014"
                        "volumen" => "370"
                        "paginaInicial" => "2071"
                        "paginaFinal" => "2082"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib107"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Programa Nacional para as Doenças Respiratórias. Direcção&#x002D;Geral da Saúde. 2012 September 05."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Programa Nacional para as Doen&#231;as Respirat&#243;rias&#46; Direc&#231;&#227;o-Geral da Sa&#250;de&#46;"
                      "idioma" => "pt"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:2 [
                        "titulo" => "Programa Nacional para as Doen&#231;as Respirat&#243;rias&#46; Direc&#231;&#227;o-Geral da Sa&#250;de&#46;"
                        "fecha" => "2012 September 05"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib108"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Research Group on Diffuse Pulmonary Diseases. Arch Bronconeumol. 2013; 49:343&#x002D;53."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis&#46; Sociedad Espa&#241;ola de Neumolog&#237;a y Cirug&#237;a Tor&#225;cica &#40;SEPAR&#41; Research Group on Diffuse Pulmonary Diseases&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.arbres.2013.03.011"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Bronconeumol. "
                        "fecha" => "2013"
                        "volumen" => "49"
                        "paginaInicial" => "343"
                        "paginaFinal" => "353"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib109"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012; 21:355&#x002D;61."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Incidence and prevalence of idiopathic pulmonary fibrosis&#58; review of the literature&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1183/09059180.00002512"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Respir Rev. "
                        "fecha" => "2012"
                        "volumen" => "21"
                        "paginaInicial" => "355"
                        "paginaFinal" => "361"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib110"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol. 2013; 5:483&#x002D;92."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Epidemiology of idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2147/CLEP.S54815"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Epidemiol. "
                        "fecha" => "2013"
                        "volumen" => "5"
                        "paginaInicial" => "483"
                        "paginaFinal" => "492"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib111"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002; 165:277&#x002D;304."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "American Thoracic Society&#47;European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias&#46; This joint statement of the American Thoracic Society &#40;ATS&#41;&#44; and the European Respiratory Society &#40;ERS&#41; was adopted by the ATS board of directors&#44; June 2001 and by the ERS Executive Committee&#44; June 2001&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/ajrccm.165.2.ats01"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med. "
                        "fecha" => "2002"
                        "volumen" => "165"
                        "paginaInicial" => "277"
                        "paginaFinal" => "304"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib112"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Idiopathic pulmonary fibrosis&#x002D;clinical presentation, outcome and baseline prognostic factors in a Portuguese cohort. Rev Port Pneumol. 2013; 19:19&#x002D;27."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Idiopathic pulmonary fibrosis-clinical presentation&#44; outcome and baseline prognostic factors in a Portuguese cohort&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.rppneu.2012.05.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Rev Port Pneumol. "
                        "fecha" => "2013"
                        "volumen" => "19"
                        "paginaInicial" => "19"
                        "paginaFinal" => "27"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib113"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Idiopathic pulmonary fibrosis: diagnosis and prognostic evaluation. Respiration. 2013; 86:5&#x002D;12."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Idiopathic pulmonary fibrosis&#58; diagnosis and prognostic evaluation&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1159/000353580"
                      "Revista" => array:6 [
                        "tituloSerie" => "Respiration. "
                        "fecha" => "2013"
                        "volumen" => "86"
                        "paginaInicial" => "5"
                        "paginaFinal" => "12"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib114"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "The genetic and environmental causes of pulmonary fibrosis. Proc Am Thorac Soc. 2012; 9:120&#x002D;5."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "The genetic and environmental causes of pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1513/pats.201112-055AW"
                      "Revista" => array:6 [
                        "tituloSerie" => "Proc Am Thorac Soc. "
                        "fecha" => "2012"
                        "volumen" => "9"
                        "paginaInicial" => "120"
                        "paginaFinal" => "125"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib115"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007; 356:1317&#x002D;26."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Telomerase mutations in families with idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa066157"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med. "
                        "fecha" => "2007"
                        "volumen" => "356"
                        "paginaInicial" => "1317"
                        "paginaFinal" => "1326"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib116"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Telomerase and telomere length in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2013; 49:260&#x002D;8."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Telomerase and telomere length in pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1165/rcmb.2012-0514OC"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Cell Mol Biol. "
                        "fecha" => "2013"
                        "volumen" => "49"
                        "paginaInicial" => "260"
                        "paginaFinal" => "268"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib117"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011; 364:1503&#x002D;12."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "A common MUC5B promoter polymorphism and pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1013660"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med. "
                        "fecha" => "2011"
                        "volumen" => "364"
                        "paginaInicial" => "1503"
                        "paginaFinal" => "1512"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib118"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PLoS ONE. 2013; 8:e70621."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1371/journal.pone.0070621"
                      "Revista" => array:5 [
                        "tituloSerie" => "PLoS ONE. "
                        "fecha" => "2013"
                        "volumen" => "8"
                        "paginaInicial" => "e70621"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib119"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "High prevalence of abnormal acid gastro&#x002D;oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006; 27:136&#x002D;42."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1183/09031936.06.00037005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Respir J. "
                        "fecha" => "2006"
                        "volumen" => "27"
                        "paginaInicial" => "136"
                        "paginaFinal" => "142"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib120"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Anti&#x002D;acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomized controlled trials. Lancet Respir Med. 2013; 1:369&#x002D;76."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis&#58; an analysis of data from three randomized controlled trials&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S2213-2600(13)70105-X"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Respir Med. "
                        "fecha" => "2013"
                        "volumen" => "1"
                        "paginaInicial" => "369"
                        "paginaFinal" => "376"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib121"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir Rev. 2013; 22:376&#x002D;81."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "The role of infection in the pathogenesis of idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1183/09059180.00000713"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Respir Rev. "
                        "fecha" => "2013"
                        "volumen" => "22"
                        "paginaInicial" => "376"
                        "paginaFinal" => "381"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib122"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Viral infection and aging as cofactors for the development of pulmonary fibrosis. Expert Rev Respir Med. 2010; 4:759&#x002D;71."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Viral infection and aging as cofactors for the development of pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1586/ers.10.73"
                      "Revista" => array:6 [
                        "tituloSerie" => "Expert Rev Respir Med. "
                        "fecha" => "2010"
                        "volumen" => "4"
                        "paginaInicial" => "759"
                        "paginaFinal" => "771"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib123"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Approach to the diagnosis of interstitial lung disease. Clin Chest Med. 2012; 33:1&#x002D;10."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Approach to the diagnosis of interstitial lung disease&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ccm.2011.12.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Chest Med. "
                        "fecha" => "2012"
                        "volumen" => "33"
                        "paginaInicial" => "1"
                        "paginaFinal" => "10"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib124"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Diagnosis of interstitial lung diseases. Mayo Clin Proc. 2007; 82:976&#x002D;86."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Diagnosis of interstitial lung diseases&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.4065/82.8.976"
                      "Revista" => array:6 [
                        "tituloSerie" => "Mayo Clin Proc. "
                        "fecha" => "2007"
                        "volumen" => "82"
                        "paginaInicial" => "976"
                        "paginaFinal" => "986"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib125"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "British Thoracic Society Standards of Care Committee; Thoracic Society of Australia; New Zealand Thoracic Society; Irish Thoracic Society. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008; 63(Suppl 5):v1&#x002D;v58."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "British Thoracic Society Standards of Care Committee&#59; Thoracic Society of Australia&#59; New Zealand Thoracic Society&#59; Irish Thoracic Society&#46; Interstitial lung disease guideline&#58; the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/thx.2008.101691"
                      "Revista" => array:6 [
                        "tituloSerie" => "Thorax. "
                        "fecha" => "2008"
                        "volumen" => "63"
                        "paginaInicial" => "v1"
                        "paginaFinal" => "v58"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib126"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Diagnosis and management of interstitial lung disease. Transl Respir Med. 2014; 2:4."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Diagnosis and management of interstitial lung disease&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/2213-0802-2-4"
                      "Revista" => array:5 [
                        "tituloSerie" => "Transl Respir Med. "
                        "fecha" => "2014"
                        "volumen" => "2"
                        "paginaInicial" => "4"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib127"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and Adjudication Processes. Chest. 2015; 148:1034&#x002D;42."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "The Idiopathic Pulmonary Fibrosis Clinical Research Network &#40;IPFnet&#41;&#58; diagnostic and Adjudication Processes&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1378/chest.14-2889"
                      "Revista" => array:6 [
                        "tituloSerie" => "Chest. "
                        "fecha" => "2015"
                        "volumen" => "148"
                        "paginaInicial" => "1034"
                        "paginaFinal" => "1042"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib128"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "The multidisciplinary approach in the diagnosis of idiopathic pulmonary fibrosis: a patient case&#x002D;based review. Eur Respir Rev. 2015; 24:69&#x002D;77."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "The multidisciplinary approach in the diagnosis of idiopathic pulmonary fibrosis&#58; a patient case-based review&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1183/09059180.00011714"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Respir Rev. "
                        "fecha" => "2015"
                        "volumen" => "24"
                        "paginaInicial" => "69"
                        "paginaFinal" => "77"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib129"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?. Eur Respir Rev. 2014; 23:308&#x002D;19."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Differential diagnosis of usual interstitial pneumonia&#58; when is it truly idiopathic&#63;&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1183/09059180.00004914"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Respir Rev. "
                        "fecha" => "2014"
                        "volumen" => "23"
                        "paginaInicial" => "308"
                        "paginaFinal" => "319"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib130"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. 2012; 186:314&#x002D;24."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Hypersensitivity pneumonitis&#58; insights in diagnosis and pathobiology&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/rccm.201203-0513CI"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med. "
                        "fecha" => "2012"
                        "volumen" => "186"
                        "paginaInicial" => "314"
                        "paginaFinal" => "324"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib131"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012; 185:1004&#x002D;14."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "An official American Thoracic Society clinical practice guideline&#58; the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/rccm.201202-0320ST"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med. "
                        "fecha" => "2012"
                        "volumen" => "185"
                        "paginaInicial" => "1004"
                        "paginaFinal" => "1014"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib132"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009; 179:1043&#x002D;7."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/rccm.200808-1313OC"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med. "
                        "fecha" => "2009"
                        "volumen" => "179"
                        "paginaInicial" => "1043"
                        "paginaFinal" => "1047"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib133"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Bronchoalveolar lavage in other interstitial lung diseases. Semin Respir Crit Care Med. 2007; 28:514&#x002D;24."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Bronchoalveolar lavage in other interstitial lung diseases&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1055/s-2007-991525"
                      "Revista" => array:6 [
                        "tituloSerie" => "Semin Respir Crit Care Med. "
                        "fecha" => "2007"
                        "volumen" => "28"
                        "paginaInicial" => "514"
                        "paginaFinal" => "524"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib134"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "The clinical utility of bronchoalveolar lavage in diffuse parenchymal lung disease. Eur Respir Rev. 2010; 19:237&#x002D;41."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "The clinical utility of bronchoalveolar lavage in diffuse parenchymal lung disease&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1183/09059180.00005510"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Respir Rev. "
                        "fecha" => "2010"
                        "volumen" => "19"
                        "paginaInicial" => "237"
                        "paginaFinal" => "241"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib135"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "The role of transbronchial biopsy in the diagnosis of diffuse parenchymal lung diseases: con. Rev Port Pneumol. 2012; 18:61&#x002D;3."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "The role of transbronchial biopsy in the diagnosis of diffuse parenchymal lung diseases&#58; con&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.rppneu.2011.09.004"
                      "Revista" => array:6 [
                        "tituloSerie" => "Rev Port Pneumol. "
                        "fecha" => "2012"
                        "volumen" => "18"
                        "paginaInicial" => "61"
                        "paginaFinal" => "63"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib136"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Lung cryobiopsies: a paradigm shift in diagnostic bronchoscopy?. Respirology. 2014; 19:645&#x002D;54."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Lung cryobiopsies&#58; a paradigm shift in diagnostic bronchoscopy&#63;&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/resp.12309"
                      "Revista" => array:6 [
                        "tituloSerie" => "Respirology. "
                        "fecha" => "2014"
                        "volumen" => "19"
                        "paginaInicial" => "645"
                        "paginaFinal" => "654"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib137"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS ONE. 2014; 9:e86716."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1371/journal.pone.0086716"
                      "Revista" => array:5 [
                        "tituloSerie" => "PLoS ONE. "
                        "fecha" => "2014"
                        "volumen" => "9"
                        "paginaInicial" => "e86716"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib138"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2015. [Epub ahead of print]"
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/rccm.200904-0493OC"
                      "Revista" => array:3 [
                        "tituloSerie" => "Am J Respir Crit Care Med. "
                        "fecha" => "2015"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            43 => array:3 [
              "identificador" => "bib139"
              "etiqueta" => "44"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008; 246:697&#x002D;722."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Fleischner Society&#58; glossary of terms for thoracic imaging&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1148/radiol.2462070712"
                      "Revista" => array:6 [
                        "tituloSerie" => "Radiology. "
                        "fecha" => "2008"
                        "volumen" => "246"
                        "paginaInicial" => "697"
                        "paginaFinal" => "722"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            44 => array:3 [
              "identificador" => "bib140"
              "etiqueta" => "45"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality. Eur Radiol. 2011; 21:1586&#x002D;93."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Fibrotic idiopathic interstitial pneumonias&#58; HRCT findings that predict mortality&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00330-011-2098-2"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Radiol. "
                        "fecha" => "2011"
                        "volumen" => "21"
                        "paginaInicial" => "1586"
                        "paginaFinal" => "1593"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            45 => array:3 [
              "identificador" => "bib141"
              "etiqueta" => "46"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Idiopathic interstitial pneumonias: a radiology&#x002D;pathology correlation based on the revised 2013 American Thoracic Society&#x002D;European Respiratory Society classification system. Curr Probl Diagn Radiol. 2015; 44:15&#x002D;25."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Idiopathic interstitial pneumonias&#58; a radiology-pathology correlation based on the revised 2013 American Thoracic Society-European Respiratory Society classification system&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1067/j.cpradiol.2014.07.005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Probl Diagn Radiol. "
                        "fecha" => "2015"
                        "volumen" => "44"
                        "paginaInicial" => "15"
                        "paginaFinal" => "25"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            46 => array:3 [
              "identificador" => "bib142"
              "etiqueta" => "47"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society. Lancet Respir Med. 2015; 3:483&#x002D;96."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials&#58; a position paper from the Fleischner Society&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S2213-2600(15)00096-X"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Respir Med. "
                        "fecha" => "2015"
                        "volumen" => "3"
                        "paginaInicial" => "483"
                        "paginaFinal" => "496"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            47 => array:3 [
              "identificador" => "bib143"
              "etiqueta" => "48"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "distinguish hypersensitivity pneumonitis from idiopathic pulmonary fibrosis?. AJR Am J Roentgenol. 1995; 165:807&#x002D;11."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "distinguish hypersensitivity pneumonitis from idiopathic pulmonary fibrosis&#63;&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2214/ajr.165.4.7676971"
                      "Revista" => array:6 [
                        "tituloSerie" => "AJR Am J Roentgenol. "
                        "fecha" => "1995"
                        "volumen" => "165"
                        "paginaInicial" => "807"
                        "paginaFinal" => "811"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            48 => array:3 [
              "identificador" => "bib144"
              "etiqueta" => "49"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Fibrosing interstitial lung disease. A practical high&#x002D;resolution computed tomography&#x002D;based approach to diagnosis and management and a review of the literature. Am J Respir Crit Care Med. 2013; 188:141&#x002D;9."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Fibrosing interstitial lung disease&#46; A practical high-resolution computed tomography-based approach to diagnosis and management and a review of the literature&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/rccm.201208-1544CI"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med. "
                        "fecha" => "2013"
                        "volumen" => "188"
                        "paginaInicial" => "141"
                        "paginaFinal" => "149"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            49 => array:3 [
              "identificador" => "bib145"
              "etiqueta" => "50"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "High&#x002D;resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005; 172:488&#x002D;93."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "High-resolution computed tomography in idiopathic pulmonary fibrosis&#58; diagnosis and prognosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/rccm.200412-1756OC"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med. "
                        "fecha" => "2005"
                        "volumen" => "172"
                        "paginaInicial" => "488"
                        "paginaFinal" => "493"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            50 => array:3 [
              "identificador" => "bib146"
              "etiqueta" => "51"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Update for pathologists on idiopathic interstitial pneumonias. Arch Pathol Lab Med. 2012; 136:1234&#x002D;41."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Update for pathologists on idiopathic interstitial pneumonias&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.5858/arpa.2012-0225-RA"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Pathol Lab Med. "
                        "fecha" => "2012"
                        "volumen" => "136"
                        "paginaInicial" => "1234"
                        "paginaFinal" => "1241"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            51 => array:3 [
              "identificador" => "bib147"
              "etiqueta" => "52"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015; 192:e3&#x002D;e19."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "An Official ATS&#47;ERS&#47;JRS&#47;ALAT Clinical Practice Guideline&#58; Treatment of Idiopathic Pulmonary Fibrosis&#46; An Update of the 2011 Clinical Practice Guideline&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/rccm.201506-1063ST"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med. "
                        "fecha" => "2015"
                        "volumen" => "192"
                        "paginaInicial" => "e3"
                        "paginaFinal" => "e19"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            52 => array:3 [
              "identificador" => "bib148"
              "etiqueta" => "53"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Comparing new treatments for idiopathic pulmonary fibrosis &#x2013; a network meta&#x002D;analysis. BMC Pulm Med. 2015; 15:37."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Comparing new treatments for idiopathic pulmonary fibrosis &#8211; a network meta-analysis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/s12890-015-0034-y"
                      "Revista" => array:5 [
                        "tituloSerie" => "BMC Pulm Med. "
                        "fecha" => "2015"
                        "volumen" => "15"
                        "paginaInicial" => "37"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            53 => array:3 [
              "identificador" => "bib149"
              "etiqueta" => "54"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag. 2015; 11:359&#x002D;70."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Update on therapeutic management of idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2147/TCRM.S69716"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ther Clin Risk Manag. "
                        "fecha" => "2015"
                        "volumen" => "11"
                        "paginaInicial" => "359"
                        "paginaFinal" => "370"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            54 => array:3 [
              "identificador" => "bib150"
              "etiqueta" => "55"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Summary of Product Characteristics: Ofev. 2015 May. Available from: <inter&#x002D;ref>http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/003821/WC500182474.pdf</inter&#x002D;ref>"
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Summary of Product Characteristics&#58; Ofev&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:2 [
                        "titulo" => "Summary of Product Characteristics&#58; Ofev&#46;"
                        "fecha" => "2015 May"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            55 => array:3 [
              "identificador" => "bib151"
              "etiqueta" => "56"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001; 134:136&#x002D;51."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Idiopathic pulmonary fibrosis&#58; prevailing and evolving hypotheses about its pathogenesis and implications for therapy&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Intern Med. "
                        "fecha" => "2001"
                        "volumen" => "134"
                        "paginaInicial" => "136"
                        "paginaFinal" => "151"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            56 => array:3 [
              "identificador" => "bib152"
              "etiqueta" => "57"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008; 68:4774&#x002D;82."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "BIBF 1120&#58; triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1158/0008-5472.CAN-07-6307"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer Res. "
                        "fecha" => "2008"
                        "volumen" => "68"
                        "paginaInicial" => "4774"
                        "paginaFinal" => "4782"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            57 => array:3 [
              "identificador" => "bib153"
              "etiqueta" => "58"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011; 37:356&#x002D;63."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Acute exacerbation of idiopathic pulmonary fibrosis&#58; incidence&#44; risk factors and outcome&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1183/09031936.00159709"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Respir J. "
                        "fecha" => "2011"
                        "volumen" => "37"
                        "paginaInicial" => "356"
                        "paginaFinal" => "363"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            58 => array:3 [
              "identificador" => "bib154"
              "etiqueta" => "59"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nintedanib: a new treatment for idiopathic pulmonary fibrosis. Clin Invest. 2015; 5:621&#x002D;32."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Nintedanib&#58; a new treatment for idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Invest. "
                        "fecha" => "2015"
                        "volumen" => "5"
                        "paginaInicial" => "621"
                        "paginaFinal" => "632"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            59 => array:3 [
              "identificador" => "bib155"
              "etiqueta" => "60"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Summary of Product Characteristics: Esbriet. 2015 May. Available from: <inter&#x002D;ref>http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/002154/WC500103049.pdf</inter&#x002D;ref>"
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Summary of Product Characteristics&#58; Esbriet&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:2 [
                        "titulo" => "Summary of Product Characteristics&#58; Esbriet&#46;"
                        "fecha" => "2015 May"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            60 => array:3 [
              "identificador" => "bib156"
              "etiqueta" => "61"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016; 47:243&#x002D;53."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Pirfenidone for idiopathic pulmonary fibrosis&#58; analysis of pooled data from three multinational phase 3 trials&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1183/13993003.00026-2015"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Respir J. "
                        "fecha" => "2016"
                        "volumen" => "47"
                        "paginaInicial" => "243"
                        "paginaFinal" => "253"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            61 => array:3 [
              "identificador" => "bib157"
              "etiqueta" => "62"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Double&#x002D;blind, placebo&#x002D;controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005; 171:1040&#x002D;7."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Double-blind&#44; placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/rccm.200404-571OC"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med. "
                        "fecha" => "2005"
                        "volumen" => "171"
                        "paginaInicial" => "1040"
                        "paginaFinal" => "1047"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            62 => array:3 [
              "identificador" => "bib158"
              "etiqueta" => "63"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010; 35:821&#x002D;9."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Pirfenidone in idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1183/09031936.00005209"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Respir J. "
                        "fecha" => "2010"
                        "volumen" => "35"
                        "paginaInicial" => "821"
                        "paginaFinal" => "829"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            63 => array:3 [
              "identificador" => "bib159"
              "etiqueta" => "64"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Long&#x002D;term clinical and real&#x002D;world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015; 24:58&#x002D;64."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1183/09059180.00011514"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Respir Rev. "
                        "fecha" => "2015"
                        "volumen" => "24"
                        "paginaInicial" => "58"
                        "paginaFinal" => "64"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            64 => array:3 [
              "identificador" => "bib160"
              "etiqueta" => "65"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib. Drug Des Dev Ther. 2015; 9:6407&#x002D;19."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Idiopathic pulmonary fibrosis&#58; current treatment options and critical appraisal of nintedanib&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Drug Des Dev Ther. "
                        "fecha" => "2015"
                        "volumen" => "9"
                        "paginaInicial" => "6407"
                        "paginaFinal" => "6419"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            65 => array:3 [
              "identificador" => "bib161"
              "etiqueta" => "66"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "High&#x002D;dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005; 353:2229&#x002D;42."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "High-dose acetylcysteine in idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa042976"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med. "
                        "fecha" => "2005"
                        "volumen" => "353"
                        "paginaInicial" => "2229"
                        "paginaFinal" => "2242"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            66 => array:3 [
              "identificador" => "bib162"
              "etiqueta" => "67"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Prednisone, azathioprine, and N&#x002D;acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012; 366:1968&#x002D;77."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Prednisone&#44; azathioprine&#44; and N-acetylcysteine for pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1113354"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med. "
                        "fecha" => "2012"
                        "volumen" => "366"
                        "paginaInicial" => "1968"
                        "paginaFinal" => "1977"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            67 => array:3 [
              "identificador" => "bib163"
              "etiqueta" => "68"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370:2093&#x002D;101."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1401739"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med. "
                        "fecha" => "2014"
                        "volumen" => "370"
                        "paginaInicial" => "2093"
                        "paginaFinal" => "2101"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            68 => array:3 [
              "identificador" => "bib164"
              "etiqueta" => "69"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo&#x002D;controlled trial results. Am J Respir Crit Care Med. 2010; 181:604&#x002D;10."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Imatinib treatment for idiopathic pulmonary fibrosis&#58; randomized placebo-controlled trial results&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/rccm.200906-0964OC"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med. "
                        "fecha" => "2010"
                        "volumen" => "181"
                        "paginaInicial" => "604"
                        "paginaFinal" => "610"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            69 => array:3 [
              "identificador" => "bib165"
              "etiqueta" => "70"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest. 2005; 128:1475&#x002D;82."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Anticoagulant therapy for idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1378/chest.128.3.1475"
                      "Revista" => array:6 [
                        "tituloSerie" => "Chest. "
                        "fecha" => "2005"
                        "volumen" => "128"
                        "paginaInicial" => "1475"
                        "paginaFinal" => "1482"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            70 => array:3 [
              "identificador" => "bib166"
              "etiqueta" => "71"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). A placebo&#x002D;controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012; 186:88&#x002D;95."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Idiopathic Pulmonary Fibrosis Clinical Research Network &#40;IPFnet&#41;&#46; A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/rccm.201202-0314OC"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med. "
                        "fecha" => "2012"
                        "volumen" => "186"
                        "paginaInicial" => "88"
                        "paginaFinal" => "95"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            71 => array:3 [
              "identificador" => "bib167"
              "etiqueta" => "72"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "A preliminary study of long&#x002D;term treatment with interferon gamma&#x002D;1b and low&#x002D;dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 1999; 341:1264&#x002D;9."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJM199910213411703"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med. "
                        "fecha" => "1999"
                        "volumen" => "341"
                        "paginaInicial" => "1264"
                        "paginaFinal" => "1269"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            72 => array:3 [
              "identificador" => "bib168"
              "etiqueta" => "73"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "A placebo&#x002D;controlled trial of interferon gamma&#x002D;1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004; 350:125&#x002D;33."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa030511"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med. "
                        "fecha" => "2004"
                        "volumen" => "350"
                        "paginaInicial" => "125"
                        "paginaFinal" => "133"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            73 => array:3 [
              "identificador" => "bib169"
              "etiqueta" => "74"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Effect of interferon gamma&#x002D;1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo&#x002D;controlled trial. Lancet. 2009; 374:222&#x002D;8."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis &#40;INSPIRE&#41;&#58; a multicentre&#44; randomised&#44; placebo-controlled trial&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(09)60551-1"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet. "
                        "fecha" => "2009"
                        "volumen" => "374"
                        "paginaInicial" => "222"
                        "paginaFinal" => "228"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            74 => array:3 [
              "identificador" => "bib170"
              "etiqueta" => "75"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo&#x002D;controlled trial. Am J Respir Crit Care Med. 2008; 178:948&#x002D;55."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Treatment of idiopathic pulmonary fibrosis with etanercept&#58; an exploratory&#44; placebo-controlled trial&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/rccm.200709-1446OC"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med. "
                        "fecha" => "2008"
                        "volumen" => "178"
                        "paginaInicial" => "948"
                        "paginaFinal" => "955"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            75 => array:3 [
              "identificador" => "bib171"
              "etiqueta" => "76"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "BUILD&#x002D;1: a randomized placebo&#x002D;controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008; 177:75&#x002D;81."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "BUILD-1&#58; a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/rccm.200705-732OC"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med. "
                        "fecha" => "2008"
                        "volumen" => "177"
                        "paginaInicial" => "75"
                        "paginaFinal" => "81"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            76 => array:3 [
              "identificador" => "bib172"
              "etiqueta" => "77"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "BUILD&#x002D;3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 184:92&#x002D;9."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "BUILD-3&#58; a randomized&#44; controlled trial of bosentan in idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/rccm.201011-1874OC"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med. "
                        "fecha" => "2011"
                        "volumen" => "184"
                        "paginaInicial" => "92"
                        "paginaFinal" => "99"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            77 => array:3 [
              "identificador" => "bib173"
              "etiqueta" => "78"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J. 2013; 42:1622&#x002D;32."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Macitentan for the treatment of idiopathic pulmonary fibrosis&#58; the randomised controlled MUSIC trial&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1183/09031936.00104612"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Respir J. "
                        "fecha" => "2013"
                        "volumen" => "42"
                        "paginaInicial" => "1622"
                        "paginaFinal" => "1632"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            78 => array:3 [
              "identificador" => "bib174"
              "etiqueta" => "79"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013; 158:641&#x002D;9."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Treatment of idiopathic pulmonary fibrosis with ambrisentan&#58; a parallel&#44; randomized trial&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.7326/0003-4819-158-9-201305070-00003"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Intern Med. "
                        "fecha" => "2013"
                        "volumen" => "158"
                        "paginaInicial" => "641"
                        "paginaFinal" => "649"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            79 => array:3 [
              "identificador" => "bib175"
              "etiqueta" => "80"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010; 363:620&#x002D;8."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1002110"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med. "
                        "fecha" => "2010"
                        "volumen" => "363"
                        "paginaInicial" => "620"
                        "paginaFinal" => "628"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            80 => array:3 [
              "identificador" => "bib176"
              "etiqueta" => "81"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 184:1390&#x002D;4."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/rccm.201101-0138OC"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med. "
                        "fecha" => "2011"
                        "volumen" => "184"
                        "paginaInicial" => "1390"
                        "paginaFinal" => "1394"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            81 => array:3 [
              "identificador" => "bib177"
              "etiqueta" => "82"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "British Thoracic Society guideline on pulmonary rehabilitation in adults. Thorax. 2013; 689(Suppl 2):ii1&#x002D;ii30."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "British Thoracic Society guideline on pulmonary rehabilitation in adults&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Thorax. "
                        "fecha" => "2013"
                        "volumen" => "689"
                        "paginaInicial" => "ii1"
                        "paginaFinal" => "ii30"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            82 => array:3 [
              "identificador" => "bib178"
              "etiqueta" => "83"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Physical Activity and Quality of Life Improvements of Patients with Idiopathic Pulmonary Fibrosis Completing a Pulmonary Rehabilitation Program. Respir Care. 2014; 59:1&#x002D;8."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Physical Activity and Quality of Life Improvements of Patients with Idiopathic Pulmonary Fibrosis Completing a Pulmonary Rehabilitation Program&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Respir Care. "
                        "fecha" => "2014"
                        "volumen" => "59"
                        "paginaInicial" => "1"
                        "paginaFinal" => "8"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            83 => array:3 [
              "identificador" => "bib179"
              "etiqueta" => "84"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "International guidelines for the selection of lung transplant candidates: 2006 update &#x2013; a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006; 25:745&#x002D;55."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "International guidelines for the selection of lung transplant candidates&#58; 2006 update &#8211; a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.healun.2006.03.011"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Heart Lung Transplant. "
                        "fecha" => "2006"
                        "volumen" => "25"
                        "paginaInicial" => "745"
                        "paginaFinal" => "755"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            84 => array:3 [
              "identificador" => "bib180"
              "etiqueta" => "85"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant Proc. 2009; 41:289&#x002D;91."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Lung transplantation in pulmonary fibrosis&#58; challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.transproceed.2008.10.042"
                      "Revista" => array:6 [
                        "tituloSerie" => "Transplant Proc. "
                        "fecha" => "2009"
                        "volumen" => "41"
                        "paginaInicial" => "289"
                        "paginaFinal" => "291"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            85 => array:3 [
              "identificador" => "bib181"
              "etiqueta" => "86"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review. Intern Emerg Med. 2015. [Epub ahead of print]"
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Acute exacerbation of idiopathic pulmonary fibrosis&#58; a clinical review&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:2 [
                        "tituloSerie" => "Intern Emerg Med. "
                        "fecha" => "2015"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            86 => array:3 [
              "identificador" => "bib182"
              "etiqueta" => "87"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Acute exacerbation of idiopathic pulmonary fibrosis&#x002D;a review of current and novel pharmacotherapies. J Thorac Dis. 2015; 7:499&#x002D;519."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3978/j.issn.2072-1439.2015.01.17"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Thorac Dis. "
                        "fecha" => "2015"
                        "volumen" => "7"
                         …3
                      ]
                    ]
                  ]
                ]
              ]
            ]
            87 => array:3 [
              "identificador" => "bib183"
              "etiqueta" => "88"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "The role of gastroesophageal reflux and microaspiration in idiopathic pulmonary fibrosis. Clin Pulm Med. 2014; 21:81&#x002D;5."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "The role of gastroesophageal reflux and microaspiration in idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            88 => array:3 [
              "identificador" => "bib184"
              "etiqueta" => "89"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol. 2006; 44:372&#x002D;6."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.vph.2006.01.013"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            89 => array:3 [
              "identificador" => "bib185"
              "etiqueta" => "90"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007; 131:897&#x002D;9."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Sildenafil improves walk distance in idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1378/chest.06-2101"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            90 => array:3 [
              "identificador" => "bib186"
              "etiqueta" => "91"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right&#x002D;sided ventricular dysfunction. Chest. 2013; 143:1699&#x002D;708."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1378/chest.12-1594"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            91 => array:3 [
              "identificador" => "bib187"
              "etiqueta" => "92"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "ARTEMIS&#x002D;IPF: a placebo&#x002D;controlled trial of ambrisentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012; 185:A3632."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "ARTEMIS-IPF&#58; a placebo-controlled trial of ambrisentan in idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [ …4]
                    ]
                  ]
                ]
              ]
            ]
            92 => array:3 [
              "identificador" => "bib188"
              "etiqueta" => "93"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "The palliative care needs for fibrotic interstitial lung disease: a qualitative study of patients, informal caregivers and health professionals. Palliat Med. 2013; 27:869&#x002D;76."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "The palliative care needs for fibrotic interstitial lung disease&#58; a qualitative study of patients&#44; informal caregivers and health professionals&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/0269216313497226"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            93 => array:3 [
              "identificador" => "bib189"
              "etiqueta" => "94"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Palliative medicine and end&#x002D;of&#x002D;life care in idiopathic pulmonary fibrosis. J Palliat Med. 2013; 16:339."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Palliative medicine and end-of-life care in idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1089/jpm.2012.0531"
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            94 => array:3 [
              "identificador" => "bib190"
              "etiqueta" => "95"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Palliative care and location of death in decedents with idiopathic pulmonary fibrosis. Chest. 2015; 147:423&#x002D;9."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Palliative care and location of death in decedents with idiopathic pulmonary fibrosis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1378/chest.14-1127"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/08732159/0000002200000002/v0_201604141122/X0873215916514648/v0_201604141122/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "50813"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Consensus"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/08732159/0000002200000002/v0_201604141122/X0873215916514648/v0_201604141122/en/320v22n02a90451464pdf001.pdf?idApp=UINPBA00004E&text.app=https://journalpulmonology.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0873215916514648?idApp=UINPBA00004E"
]

Article information

ISSN: 08732159
Original language: English

DOI:10.1016/j.rppnen.2016.01.003

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	19	5	24
2024 October	106	26	132
2024 September	92	27	119
2024 August	139	39	178
2024 July	120	62	182
2024 June	78	49	127
2024 May	134	55	189
2024 April	64	34	98
2024 March	103	31	134
2024 February	59	29	88
2024 January	71	29	100
2023 December	157	27	184
2023 November	50	42	92
2023 October	26	30	56
2023 September	21	29	50
2023 August	13	24	37
2023 July	16	45	61
2023 June	48	23	71
2023 May	65	21	86
2018 September	3	0	3
2018 August	19	1	20
2018 July	21	1	22
2018 June	18	0	18
2018 May	23	0	23
2018 April	14	3	17
2018 March	29	0	29
2018 February	10	0	10
2018 January	18	1	19
2017 December	26	1	27
2017 November	19	0	19
2017 October	22	0	22
2017 September	24	2	26
2017 August	19	2	21
2017 July	30	2	32
2017 June	16	2	18
2017 May	39	3	42
2017 April	12	2	14
2017 March	3	1	4
2017 February	5	1	6
2017 January	4	3	7
2016 December	5	3	8
2016 November	9	2	11
2016 October	14	2	16
2016 September	7	1	8
2016 August	13	1	14
2016 July	15	7	22
2016 June	1	0	1
2016 May	4	132	136
2016 April	216	49	265

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter